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INTRODUCTION 
An early step in the control of gene replication and 
expression is exerted through the template functions of 
1 
the genome. Synthesis of RNA, in particular, appears to be 
controlled by cell constituents that can repress or enhance 
gene expression by associating with specific sites of the 
DNA molecule. Reduction or enhancement of transcription 
can also be induced artificially through the introduction 
of chemical agents that can interact with and alter the 
template capacity of the DNA molecule for nucleic acid 
synthesis. One such agent is ethidium bromide, a drug be-
longing to the family of phenanthridines, compounds 
characterized by the presence of a phenanthridinium ring 
system in the molecule. Ethidium bromide is believed to 
owe its pharmacological and biological activity, at least 
in part, to its ability to reach and bind to the DNA 
molecules of the cell .i!J. vivo {Waring, 1972). l!!. vitro, 
ethidium bromide has been shown to bind to DNA as well and 
inhibit RNA synthesis as a result of this interaction 
{Waring, 1965). The formation of the DNA-ethidium bromide 
complex is accompanied by characteristic changes in the 
physicochemical properties of both constituents of the 
complex, a fact that has facilitated the study of their 
interaction. As a result, the DNA-ethidium bromide complex 
2 
has been the subject of numerous studies. The inhibitory 
effectiveness of ethidium bromide against enzymes utilizing 
DNA as either substrate or template has also been studied. 
Despite considerable accumulation of knowledge 
regarding the biological properties of ethidium bromide, 
very little is known about the interaction of other phenan-
thridines with nucleic acids although the pharmacological 
activity of many of these structural analogs of ethidium 
bromide has been extensively tested. Very recently the 
optical and hydrodynamic properties of some phenanthridine-
DNA complexes have been studied and were found to be similar 
to the properties of the parent compound {Waring, 1974; 
Aktipis and Kindelis, 1973a,b). The inhibitory effective-
ness of these compounds against DNA-dependent DNA polymerase 
I and pancreatic deoxyribonuclease I is also comparable with 
that of ethidium bromide (Aktipis and Kindelis, 1974). 
The subject of the present study is the mechanism of 
inhibition of RNA synthesis by structural analogs of ethidium 
bromide. Information pertinent to the factors and parameters 
governing RNA synthesis, as well as the mechanism of the 
reaction, is presented below. 
1. The Pharmacological and Biological Properties of 
Ethidium Bromide and its Structural Analogs 
The pharmacological activity of a large number of 
phenanthridines has been extensively investigated. The 
3 
early discovery of antitrypanosomal action (Brownlee et !J..., 
1950) was soon followed by reports on the antibacterial 
(Seaman and Woodbine, 1954) and antiviral (Dickinson et !J..., 
1953) activities of these drugs and later on the antileukemic 
activity of ethidium bromide on experimental animals (Gosse 
~ !l·' 1974). Apart from its pharmacological action 
ethidium bromide has been shown to exert an effect on a 
variety of biological functions as well (Waring, 1972). At 
the cellular level ethidium bromide has been found to induce 
petite mutation in yeast (Slonimski !! !J..., 1968) to bind 
cooperatively to mitochondrial membranes (Azzi and Santato, 
1971) and to eliminate plasmids from the bacterial cytoplasm 
(Bouanchaud et !J..., 1968). At the molecular level ethidium 
bromide has been reported to inhibit mitochondrial RNA 
synthesis (Zylber and Penman, 1969) and mitochondrial DNA 
replication in yeast (Nagley et al., 1973) while, in duck 
cells infected by avian sarcoma virus, ethidium bromide 
inhibits the appearance of closed circular viral DNA 
(Guntake!! !l·' 1975). The apparent selective inhibition 
of exonuclear DNA's by ethidium bromide is thought to reside 
in the higher affinity of the drug for supercoiled DNA 
molecules (Waring, 1972; Hixon et !l·• 1975). 
4 
In vitro studies have revealed that ethidium bromide is 
a strong inhibitor of DNA polymerase I {Elliott, 1963; Mayer 
and Simpson, 1969), deoxyribonuclease I {Eron and McAuslan, 
1966), RNA polymerase {Waring, 1965) and reverse transcriptase 
{MUller~ !!·• 1971). 
Structural analogs of ethidium bromide examined for 
in vitro activity on DNA polymerase I and pancreatic deoxy-
ribonuclease were found to be strong inhibitors of both 
enzymes {Aktipis and Kindelis, 1974). 
2. The St~ucture and Properties of the DNA-Drug 
Complex 
5 
In 1964, Fuller and Waring assigned a tentative 
structure to the complex of DNA with ethidium bromide based 
on evidence obtained through fiber x-ray diffraction studies 
and molecular model building. In that report, it was 
postulated that the planar part of the ethidium bromide 
molecule, i.e., the phenanthridinium ring is inserted (Table 
1}, in a parallel fashion to the two adjacent base pairs of 
double stranded DNA; i.e., present in an intercalation site. 
Insertion of the phenanthridinium ring system between 
adjacent base pairs was postulated to occur in such a 
fashion so as to bring the two amino groups at positions 3 
and 8 of the molecule (Table 1} within bonding distance 
from the two phosphate groups located opposite each other 
on the two DNA strands. As a consequence, the intercalated 
molecule should be stabilized by hydrophobic forces, 
including n-n interactions between ethidium bromide and the 
neighboring bases. and both hydrogen bonding and electro-
static forces between the amino groups on the drug molecule 
and the phosphate groups of the DNA. In order to accommodate 
the intercalated ethidium bromide molecule, the two adjacent 
base pairs had to be translocated relative to each other, 
resulting in a local unwinding of the double helix. The 
unwinding angle, i.e., the reduction of the 36° helical 
rotation between two successive base pairs due to the 
insertion of one ethidium bromide molecule, was found to 
be 12° at the point of intercalation. 
The proposed model could account not only for most 
6 
of the experimental evidence available at that time, but 
also permitted some predictions to be formulated about the 
properties of the complex, which have since been sub-
stantiated by experiment. Insertion of the phenthridinium 
ring between adjacent base pairs should stabilize the ·double 
helix as well as unwind it locally resulting in an overall 
length increase of the DNA molecule. Temperature transition 
profiles and electron microscopy in the presence and absence 
of ethidium bromide have verified these predictions (Waring, 
1966; Freifelder, 1971). The presence of numerous ethidium 
bromide molecules intercalated on the DNA helix has also 
been found to cause an increase in the intrinsic viscosity 
of the macromolecule that has been attributed to the increase 
in the length of DNA (Douthard et !!·, 1973) and a decrease 
in the sedimentation coefficient due to the decrease in 
the length-specific mass of the complex relative to the 
uncomplexed DNA molecule (Douthard et !]_., 1973). The 
sedimentation coefficient of supercoiled double-stranded 
circular DNA, on the other hand, is strongly affected by 
increasing concentrations of bound ethidium bromide (Crawford 
and Warfng, 1967). This behaviour has been attributed to the 
fact that the sedimentation coefficient of supercoiled DNA 
••• ~ . 
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~olecules is largely determined by the number of superhelical 
turns in the molecule (T). T is in turn connected with the 
ratio of the number of base pairs (N) over the double helix 
pitch {p) by the expression: T = a - ~ (Crawford and Waring, 
1967) where a is a topological linking number. a and N are 
constant for any given circular DNA molecule. Therefore, 
when the helix pitch is altered by the binding of ethidium 
bromide, the number of superhelical turns and the sedimenta-
tion coefficient of the superhelical DNA will be affected. 
The excellent agreement between extensive theoretical and 
experimental considerations of this phenomenon render it the 
best piece of evidence in favor of the intercalation model. 
In fact, this method is now being used in order to test other 
drugs for possible intercalative binding, or in the opposite 
sense, in order to test new DNA molecules for circularity 
(Waring, 1972). 
The optical properties of ethidium bromide show char-
acteristic changes in the visible spectrum when this drug 
associates with DNA. Upon binding to a double-stranded 
nucleic acid, the absorption spectrum of ethidium bromide 
undergoes a bathochromic and hypochromic shift with the 
appearance of two well-defined isosbestic points in the 
visible region of the spectrum (Waring, 1965). Also the 
fluorescence quantum yield of ethidium bromide increases 
·drastically (Le Pecq and Paoletti, 1967). The circular 
8 
dichroism and optical rotatory dispersion spectra of the DNA-
. ethidium bromide complex show characteristic bands in the 
visible region of the spectrum, a consequence of the presence 
of the absorbing drug chromophore in an asymmetric environment 
(Aktipis and Martz, 1970; Dalgleish et !!·, 1971; Aktipis and 
Kindelis, 1973). 
The kinetics of formation of the intercalation complex 
between ethidium bromide and transfer-RNA have also been 
studied. The results are best fitted by a mechanism in which 
ethidium bromide intercalates following a two-step, three-
component pathway. In the first step, ethidium bromide and 
the DNA (two components) interact to form a complex (the third 
component) in which ethidium bromide is bound on the outside 
of the DNA helix. Subsequently, ethidium bromide from this 
complex is inserted between the DNA base pairs in a mono-
molecular, rate-limiting step (Tritton and Mohr, 1971). 
Studies on the kinetics of association of ethidium 
bromide with double-stranded DNA suggest that in addition to 
the above mechanism intercalated ethidium bromide molecules 
can also be transferred between intercalation sites in a 
direct exchange reaction (Bresloff and Crothers, 1975). 
Kinetic experiments of the association of actinomycin D 
and proflavine, two other well characterized intercalators, 
support the two-step, three-component mechanism as a general 
kinetic model for intercalation (Li and Crothers, 1969; 
MUller and Crothers, 1968). 
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However, some revisions to the original._intercalation 
model may be necessary in view of the recent x-ray diffraction 
studies on crystalline samples of ethidium bromide double-
stranded oligonucleotide complexes (Tsai et !l., 1975). These 
studies conclude that the overall geometry of the ethidium 
bromide molecule in the intercalation site is in agreement 
with the conformation proposed by Fuller and Waring, although 
the drug molecule is now placed in the minor groove of the 
DNA and the unwinding angle of the helix is found to be 26° 
per intercalated drug molecule rather than the 12-14° angle 
predicted by the Fuller-Waring model. Recent hydrodynamic 
studies with double-stranded circular DNA have also resulted 
in a value of 26° for the unwinding angle (Wang, 1974). 
The conformation and the properties of DNA complexes 
formed with structural analogs of ethidium bromide have 
received very little attention. The binding parameters of 
some of these compounds and ethidium bromide to double-
stranded DNA have been found to be of similar magnitude to 
one another and the'optical properties of their DNA complexes 
share some common features (Kindelis, 1976). 
Direct evidence that ethidium bromide analogs also 
bind to DNA by intercalation has been obtained with circular 
DNA by examining the dependence of the sedimentation coefficient 
on the concentration ~f bound drug as discussed previously. 
From these expe~iments it was concluded that the ability of 
10 
the structural analogs of ethidium bromide to bind to DNA by 
intercalation is maintained even among compounds carrying 
~ extensive substitution on the phenanthridinium ring system 
~Wakelin and Waring, 1974). However, compounds lacking the 
amino group at position 8 of the phenanthridinium ring 
exhibit characteristic fluorescence and circular dichroism 
spectra indicating that the DNA complexes of these analogs 
may exist in the intercalation site in conformations 
different than those of ethidium bromide and the other. 
diamino derivatives (Kindelis, 1976). 
f n 3. The Mechanism of Transcription 
t . 
RNA synthesis catalyzed by bacterial DNA-dependent 
RNA polymerase and viral DNA as template is a multistep 
process involving initial binding of the enzyme at non-
specific DNA sites followed by recognition of a specific 
. . 
1 1 
site, formation of the first phosphodiester bond, elongation 
of the product chain and, finally, termination (Burgess !1 !!., 
1969). With T2 or T4 DNA as template, RNA synthesis may 
only be catalyzed by holoenzyme; i.e., core enzyme consisting 
of the four stable subunits (a2ee') plus the less stable cr 
subunit (Burgess et !!·' 1969). The cr subunit is necessary 
for the enzyme to recognize the correct initiation site on 
viral DNA templates (such as T7, T4 or T2 DNA) and is released 
during chain elongation (Travers and Burgess, 1969). Although 
the exact mechanism of action of the cr factor is unknown at 
the present time it is thought that perhaps it binds to the 
core enzyme and may act as an allosteric effector to the 
holoenzyme. Chain elongation with T7 DNA as template yields 
in vitro a major RNA product which is approximately 7,000 
nucleotides long (Millette et !l·, 1970), while with T2 or 
T4 DNA the average chain length is approximately 5,000 
nucleotides (Richardson, 1970; Maitra and Barash, 1969). The 
rate of chain growh ~vivo is comparable to the rate of 
growth in vitro, which with T7 DNA has a value of 36 n~cleo­
tides per sec while with T4 DNA this figure is only 22 
nucleotides per sec (Bremer, 1970). Since the growth rate 
of RNA chains with T2 DNA as template is slower than with 
12 
T7 DNA while the length of the transcript with either template 
is of comparable size, termination of chain elongation should 
not occur within 90 sec of assay time with T2 DNA as template. 
The growth rate with T2 DNA which is used in this work would 
be expected to be comparable to that of T4 DNA, since the two 
molecules have been shown to possess similar chemical, 
biological and genetic properties (see for example Rau~h, 
1965). Although completion of a long transcript in vitro 
requires approximately 2 min, addition of one nucleotide to a 
growing chain requires only a small fraction of a second. 
This rate is very fast compared with the time required for 
half the enzyme to locate the initiation sites, which is 
15-20 sec (Hinkle and Chamberlin, 1972). 
Despite the fact that the values of the kinetic para-
meters governing the various steps of RNA synthesis have 
been determined repeatedly in many laboratories, common 
agreement on their exact magnitude is difficult to achieve. 
Due to the complexity of the reaction, these kinetic para-
meters are influenced by a great number of factors, such 
. ++ ++ as temperature, KCl concentrat1on, Mg and/or Mn concen-
tration, the concentration of template relative to enzyme, 
the nature of the template, the a-subunit content pf the 
enzyme preparation, the nucleotide substrate concentration, 
the sequence of addition of the various components in the 
r 13 
~ 
J r assay mixture, the pre~incubatton and incubation time, the 
method of collecting the product, to name only a few.· Some 
of these factors are bound to vary from one set of conditions 
to another, making direct comparison of literature values 
very difficult. 
Even a brief review_ of the ways in which these factors 
might influence the process of RNA synthesis becomes a nearly 
impossible task and, for most purposes, a meaningless one. 
Because of the enormous complexity of the system catalyzing 
this reaction, many factors which might facilitate the rate 
of one step might be deleterious to another. To give only 
one example, raising the salt concentration from 0.05 M to 0.2 M 
increases the rate of elongation, whereas, it decreases the 
number of RNA chains that can be initiated. At the same time, 
RNA polymerase molecules which complete the synthesis of one 
chain are released from the template and are able to reinitiate 
a new chain in 0.2 M KCl, but only to a smaller extent in 
0.05 M KCl (Bremer, 1970). What are, then, the optimal salt 
conditions for RNA synthesis? The answer to this question is, 
naturally, that the effect of each factor should be examined 
separately for each step. Then, the importance of techniques 
which would be able to isolate the events of each particular 
step becomes evident. 
One method for studying the events of RNA chain initia-
tion and chain elongation independently but simultaneously has 
been described by Maitra and Hurwitz (1965). This method 
relies on the fact that, among all the ribonucleotides to 
14 
be incorporated into the RNA product, only the first one 
will maintain its e andy phosphate groups intact. One 
could, therefore, use a nucleoside triphosphate substrate 
labelled on the terminal phosphate with 32P and on the 
purine or pyrimidine ring with 3H or 14c. Incorporation of 
32 P in the product would then be a measure of the number of 
chains initiated with that particular nucleotide, while 
incorporation of 3H {or 14 c) would be a measure of the over-
all rate of RNA synthesis. The ratio of 3H over 32 P would 
be a measure of the length of the product chain. Using 
this method, it was found that the large majority {> 90%) 
of all product chains are initiated with either an ATP or 
GTP as the first nucleotide. The ratio of chains initiating 
with ATP over those initiating with GTP was found to be a 
function of many factors and varied between 6/l and 1/1 
with intact T4 DNA as template {Maitra et al., 1967). 
Denaturation of the DNA or reduced content of a-factor for 
the enzyme increased the number of chains initiating with 
GTP. An excellent review article covering the information 
available on RNA synthesis prior to 1974 has recently been 
published {Chamberlin, 1974). 
In 1974, new methods were developed allowing further 
resolution of the events that take place during chain 
initiation {Mangel and Chamberlin, 1974a; b; c). This 
15 
achievement was accom~lished by exploiting the property-of 
the drug rifampicin to attack and inactivate RNA polymerase 
molecules at greatly different rates, depending upon 
whether these enzyme molecules are going through initiation, 
elongation or are free in solution. Template-bound RNA 
polymerase molecules are inactivated approximately 100 times 
slower than free enzyme molecules while elongating polymerase 
molecules are truly resistant to rifampicin. The second 
order rate constant of rifampicin attack on holoenzyme-T 7 
DNA complex is 3.5 x 103 M-l s- 1 (Hinkle et !!·• 1972). 
Mangel and Chamberlin formed complexes of I· coli RNA 
polymerase with bacteriophage T7 DNA at 37°C in the absence 
of ribonucleotide substrates. Then, the reaction was 
initiated by the addition of a mixture of the four ribo-
nucleotides with rifampicin and was allowed to proceed for 
90 sec. In this period of time, the enzyme-DNA binary 
complex (RS) can have one of two fates: a) it may be 
inactivated by rifampicin; or b) it may react with a nucleo-
tide and form a ternary initiation complex (OP} which is 
resistant to rifampicin and forms product uninhibited. If 
this scheme is correct, Mangel and Chamberlin argue, the 
ratio of the rate of the reaction in the absence of 
rifampicin over the rate of the reaction in its presence 
plotted as a function of increasing rifampicin concentra-
tions should be a straight line of characteristic slope and 
jntercept: The intercept on the rate axis should be a 
m~~sure of the number of RNA polymerase molecules which 
are able to escape rifampicin and form product, while the 
slope should be equal to the ratio of the second-order 
rate constant of rifampicin attack on the binary enzyme-
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DNA complex (RS), over the rate constant of the transfor-
mation of the RS complex to the rifampicin-resistant ternary 
complex (OP). Experiments conducted under a variety of 
nucleotide concentrations verified these predictions -and 
allowed the calculation of a value of 5 s- 1 for the pseudo-
first order rate constant governing the transformation of 
the RS to the OP complex with T7 DNA at 0.4 mM XTP (Mangel 
and Chamberlin, 1974). 
However, the results of similar experiments, conducted 
under various temperature and ionic strength conditions, 
indicated that another state (I) might exist for the enzyme-
DNA binary complex, from which the enzyme could rapidly 
equilibrate with the RS complex. Formation of the I complex 
is favored over the RS complex at low (< 10°C) temperature 
and high (> 0.1 M KCl) salt concentrations (Mangel and 
Chamberlin, 1974b; c). In order to measure the rate of 
transformatjon of the I to the RS complex, I complexes were 
formed by incubating E. coli RNA polymerase and T7 DNA at 
ooc under low salt (< 0.05 M KCl) conditions. Subsequently, 
the mixtures were transferred into a 37°C bath for increasing 
periods of time (pre-incubation). RNA synthesis was then 
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initiated by the addition of a mixture of rifampicin and 
the four ribonucleotide substrates and terminated 90 sec 
later. With increasing pre-incubation time, an increasing 
fraction of RNA polymerase molecules would find the necessary 
time and be transformed from the I to the RS complex. Then, 
the fraction of enzyme molecules still at I complexes would 
be inactivated by rifampicin upon addition of the rifampicin-
nucleotide mixture, while the majority of the RS complexes 
would be able to initiate an RNA chain. It was indeed 
shown that the rate of rifampicin attack on I complexes is 
much faster than the rate of transformation of I to RS 
(Chamberlin and Ring, unpublished observations, cited by 
Chamberlin, 1974). Consequently, Mangel and Chamberlin 
argued and demonstrated experimentally a plot of the rate 
of the reaction as a function of pre-incubation time must 
yield an exponential curve having a slope equal to the 
first order rate constant of the transformation of the I 
to the RS complex. The half-life time of this transforma-
tion was found to be approximately 22 sec under the 
conditions of their assay. 
Based on the evidence obtained with these methods, 
Mangel and Chamberlin postulated that at least two steps 
may be distinguished in the process of RNA chain initiation 
between the time the initial binding_ of the enzyme at the 
specific recognition site on the DNA template takes place 
and the subsequent formation of the first phosphodiester 
bond (Scheme I). In the.first initiation step, an enzyme 
molecule already bound on a specific DNA recognition site 
in a highly stable rifampicin-sensitive binary complex 
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(I) transforms into a rapidly-starting (RS) complex. This 
transformation occurs via a temperature dependent, rate-
limiting transition that may involve partial unwinding of 
the DNA helix as well as translocation of the enzyme along 
the template. In the second initiation step the binary 
(RS) complex forms a rifampicin-resistant ternary initia-
tion complex (OP) by forming the first phosphodiester bond. 
This latter step does not seem to involve translocation of 
the enzyme along the template (Heyden et !l·• 1975). 
The methodology of Mangel and Chamberlin was described 
in some detail here not only because of its significance but 
also because it is being used in this work in order to study 
the effect of various inhibitors of RNA synthesis on each 
initiation step. 
Application of one of these methods had already 
allowed direct measurement of the effect of the number of 
superhelical turns of a closed circular DNA on the second 
initiation step. It turns out that superhelicity does not 
have any significant effect on the second initiation step 
(Richardson, 1975). On the other hand, the presence of 
superhelical turns on the molecule appears to greatly 
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s~heme I. The mechanism of RNA synthesis. The line 
represents a hypothetical tem~late molecule and the dark 
discs an RNA polymerase molecule. For schematic purposes, 
different DNA sites have been assigned to each complex 
and are depict~d either in the "closed," 
----1---; or in 
the "open," ----•---, configuration. 
NS I RS OP EL 
.41---------------~ ~-----------41t--
Description 
NS Non-specific binding - formation of non-specific 
complex NS 
I Recognition - formation of the I complex 
RS First initiation step - formation of the RS complex -
DNA strand separation 
OP Second initiation step - formation of the first 
phnsphodiester bond, ternary OP complex 
EL Elongation steps - formation of the elongation 
complexes EL 
20 
facilitate the temperature dependent transition through 
step 1 {Hayashi and Hayashi, 1971). However, it is not 
known whether superhelicity affects the number or the rate 
of enzyme molecules going through the first initiation step. 
These recent advances in the understanding of the 
mechanism of RNA synthesis ~vitro have provided clues as 
to the possible mode of action of the various transcriptional 
control elements ~ vivo. For instance, one type of a DNA-
binding protein {the CAP protein) has been identifie~ 
which facilitates the initiation of transcription in vivo. 
Binding of the CAP protein to the DNA induces a structural 
transition of the template which may facilitate the formation 
of the {RS) complex (Dickson et !l·• 1975). 
4. The Mechanism of Inhibition of RNA Synthesis 
Through Template Inactivation 
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Chemical agents that attack and permanently modify 
the primary and/or the secondary structure of the DNA are 
known to interfere with the template properties of the 
macromolecule (Waring, 1972; BUcher and Sie, 1969). Inhi-
bition of RNA synthesis, however, may also result from 
the interaction of the DNA molecule with compounds that 
bind reversibly and alter the conformation of the double 
helix only for that period of time during which they 
remain associated with the template. For example, com-
pounds that bind to DNA by intercalation between base 
pairs like ethidium bromide, proflavine or actinomycin D, 
are strong but reversible inhibitors of RNA synthesis. 
These compounds however exert their inhibitory effect on 
RNA polymerase through various modes of action. Specifically, 
although ethidium bromide, proflavine and actinomycin D all 
inhibit the overall rate of RNA syrithesis, each one of 
these compounds does so by affecting different steps of the 
overall reaction. Actinomycin D up to a given concentration 
interferes only with RNA chain elongation (Sentenac et !!·• 
1968; Hyman and Davidson, 1970) while ethidium bromide 
affects almost exclusively chain initiation (Richardson, 
1973a). Proflavine has been found to inhibit both steps 
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and to approximately the same extent (Hurwitz et _ti., 1962; 
1967; Richardson, 1966a and b). 
Ethidium bromide has been the best studied initiation 
inhibitor to date. The activity of this compound as an 
inhibitor of RNA synthesis has been found to vary with the 
type of template employed and this variation does not appear 
to result from the small differences noted in the affinity 
of this compound for each different DNA template {Richardson, 
1973b). 
Binding of ethidium bromide on the DNA-template at 
concentrations causing total inhibition of RNA synthesis 
does not appear to interfere with the binding of RNA poly-
erase at non-specific sites on the template {Richardson, 
1973a). On the other hand, ethidium bromide has been found 
to inhibit the formation of the strong complexes of RNA 
polymerase with specific sites of the template, as 
evidenced by the decrease in the amount of complexes w~ich 
are retained on a cellulose nitrate filter in the presence 
of inhibitor (Richardson, 1973a). This inhibition of the 
strong binding of RNA polymerase by ethidium bromide 
appears to result from the inability of the enzyme to form 
complexes with the specific sites of the template in,the 
presence of ethidium bromide molecules intercalated in the 
vicinity of those sites. RNA polymerase, however, has the 
ability to displace ethidium bromide from its strong 
binding sites while ethidturn bromide, which has a much 
weaker affinity for the template than the enzyme, is 
unable to induce dissociation of the enzyme from its 
strong (cellulose nitrate non-filterable) complexes 
(Richardson, 1973a). 
However, no quantitative correlation has been 
attempted between the degree to which specific binding 
of the polymerase to the template is inhibited and the 
inhibition of RNA chain initiation (Richardson, 1973a). 
Moreover, it is not known which one of the specific 
enzyme-DNA complexes described in the previous section 
(Scheme I) is inhibited by the template-bound form of 
the drug. Neither is it known whether ethidium bromide 
inhibits by causing a reduction in the rate of formation 
of specific enzyme-DNA complexes or by causing a decrease 
in the number of such complexes that can be formed in the 
presence of this inhibitor (or perhaps, by a combination 
of the above two modes of inhibition). 
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A study of the effects of ethidium bromide and some 
of its structural analogs on the number and the rate of RNA 
polymerase molecules involved in product formation has 
been the main goal of this investigation. Since at least 
five individual steps are presently recognized in RNA 
synthesis (Scheme I) the effect of each inhibitor on the 
number and the rate of RNA polymerase molecules traversing 
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each one of these steps has separately been studied. The 
results indicate that ethidium bromide and its structural 
analogs inhibit RNA synthesis as a result of their presence 
in the vicinity of a specific DNA site which must be 
recognized by RNA polymerase in order for the first 
productive enzyme-DNA complex to be formed. 
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MATERIALS AND METHODS 
Nucleoside triphosphates (sodium salts) were purchased 
either from Sigma or from P-l Biochemicals specified as at 
least 98% pure. Tritium or 32P-labelled nucleotides were 
purchased either as freeze-dried ~mmonium salts or as 50% 
ethanolic solutions (Amersham-Searle}. In the latter case, 
the ethanol was blown off under a stream of nitrogen before 
use. Both tritium and 32P-labelled nucleotides were 
purchased at a specific activity of more than 15 Ci/mmol and 
were diluted to the desired specific activity with unlabelled 
material. Calf thymus DNA was purchased from Worthington 
Biochemical Corporation. Bacteriophage T2 was obtained 
from Miles laboratories at a concentration of 5-10 x 1012 
virus particles per ml and a titer of 2.1 x 1012 plaque 
forming units per ml. 
1. I 2 DNA Preparation 
The method described by Bautz and Dunn (1971) was 
used for the isolation of T2 DNA. 
Six milliliters of the commercial virus suspension 
was dialyzed against 2.0 1 of 0.1 M sodium phosphate buffer 
pH 7.2 for ·three hours. The dialyzate was transferred to 
a 15 ml conical glass tube and 0.11 volume (0.66 ml) of a 
freshly prepared 10% sodium dodecyl sulfate solution was 
added. The mixture was bro~ght to 65°C for 3 min, th•n 
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rapidly chilled in ice and 1.0 M KCl was added to the 
solution to make it 0.3 M in KCl. After 15 min centrifuga-
tion in the cold (IEC SB206 rotor, 27,000 g), an equal 
volume of freshly distilled phenol (saturated with 0.1 M 
sodium phosphate buffer pH 7.2 and containing 0.08% a-
hydroxyquinoline} was added to the supernatant and the 
mixture was rocked for 14 min at a frequency of 40 rpm/min. 
Centrifugation for 15 min in an IEC clinical, swinging 
bucket centrifuge at top speed separated the phenol layer 
{yellow) which was discarded with the help of a Pasteur 
pipette, from the buffer layer which was dialyzed against 
4.0 1 0.01 M Tris-HCl, 0.01 M KCl, 0.00005 M EDTA pH 7.9 
with three changes for four days. The purified T2 DNA 
solution was stored at -20°C in five 2 ml aliquots. The 
concentration of the product (0.0010 M in nucleotide) was 
determined spectrophotometrically assuming a molar extinction 
coefficient of 6500 at 260 nm and a nucleotide mean molecular 
weight of 357 (Rubenstein~ !l·, 1961). The A2601280 ratio 
of the product was 1.80 and the A2601230 ratio was 2.1, 
indicating very low protein contamination (Thomas and 
Abelson, 1966). 
2. The Enzyme 
Escherichia coli K-12 DNA-dependent RNA polymerase 
(EC 2.7.7.6) was purchased from Sigma Chemical Co. as a 
50% glycerol solution having a specific activity of ·396 
27 
units per mg protein (2.1 mg protein/ml of solution) using 
the unit definition of Burgess (1969) with calf-thymus DNA 
as template. Enzymatic activity assays carried out in the 
laboratory under identical conditions yielded a value of 
BOO units per ml of solution with calf-thymus DNA as 
template, but a value of 1600 units per ml of solution with 
T2 DNA as template. Higher enzymatic activity with T2 DNA, 
as compared to calf-thymus DNA, is indicative of an enzyme 
having a high content of a-subunit (Burgess, 1969) .. Indeed, 
the rifampicin experiments described below {section 6a of 
Results) indicate that the RNA polymerase had approximately 
65% of the activity expected if all enzymatic protein were 
active holoenzyme {Mangel and Chamberlin, 1974a). 
3. The Inhibitors 
Actinomycin D was obtained from Calbiochem. Rifampicin 
was obtained from Sigma. Ethidium bromide was purchased from 
i C•lbiochem. Ethidium bromide analogs were the generous gift 
~ 
of Dr. T. I. Watkins of Boots Company Ltd., Nottingham, 
England. The chemical formulae, molecular weights, molar 
extinction coefficients and DNA binding parameters of these 
compounds are given in Table 1 (seep. 39). The molar ex-
tinction c~efficients shown in this Table are based on the 
formula weight of the compounds and were determihed from the 
absorption spectra of carefully prepared solutions at a 
concentration of 1-2 mg/25 ml in 0.04 M Tris-HCl pH 7.9 at 
room temperature. More detailed studies of the optical 
properties of the DNA complexes of these compounds are 
described by Kindelis (1976). 
4. Determi'nation of Binding Parameters 
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The spectrophotometric method of Peacocke and Skerett 
(1956) was used to determine the binding constant and the 
maximum number of binding sites per DNA nucleotide for each 
drug on calf-thymus DNA. 
In a typical experiment, calf-thymus DNA (2-3 mg/ml) 
was dissolved under slow stirring at a-5°C in binding buffer 
consisting of a.2 M KCl, a.a4 M Tris-HCl, a.al M MgC1 2, 
0.1 mM EDTA, a.32 mM K2HPa 4 , pH 7.9. Then, the solution 
was dialyzed overnight against binding buffer at a-5°C, and 
filtered by suction through a GF/C filter (Whatman). The 
concentration of DNA in the filtrate was determined spectra-
photometrically in the Cary 15 at 26a nm, using a molar 
ex.tinction coefficient of 66aO (Mahler~ !l_., 1964). 
Solutions of increasing DNA/drug ratio were prepared 
by adding increasing amounts of the DNA solution into 
constant amounts of the drug solution in binding buffer 
and bringing the mixture to the same final volume (la ml) 
f with buffei. Identical solutions containing DNA, but no 
inhibitor, were also prepared and used as reference in 
the double-beam Cary 15 spectrophotometer. The total 
drug concentration (I ) was determined from the absorption 
0 
,. 
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spectrum of a solution prepared as above, but in the absence 
of DNA. The amount of drug (around 20 ~M) was chosen so 
that the absorbance at Amax of the resulting solution would 
be approximately 1.0. After mixing, each solution was 
transferred into a 10.00 em path, water jacketed optical 
cell (Hellma) that was kept at 37°C with the help of a 
Lauda K-2R constant temperature circulator, and after 
thermal equilibration the difference absorption spectrum 
was recorded vs. the corresponding reference solution. 
The absorption spectra of the DNA complexes of all 
the drugs examined displayed the qualitative features 
described by Kindelis (1976) for the complexes of the same 
compounds formed under different ionic environment. In 
every case sharp isobestic points were observed in the 
area 380-400 nm and 460-500 nm. 
The absorbance of each sample (Ax) and that of the 
11 total 11 drug (A 0 ) were read off the chart paper at a given 
wavelength, chosen for best accuracy so that A0 -Ax is 
maximum. 
The absorbance of the completely bound drug {Ab) 
was calculated with the graphic method of Li and Crothers 
(1969) who have demonstrated that a plot of l/A 0 -Ax !!· 
l/[DNA]-[1 0 ] yields a straight line with an intercept on 
the ordinate equal to l/A 0 -Ab. From the value of this 
intercept, Ab may be calculated. Determination of Ab with 
this graphic method is much more accurate than the alternative 
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method of reading off the chart paper the absorbance of a 
solution prepared with very high DNA concentration (at very 
high DNA concentration all of the drug is assumed to be 
bound; i.e., Ax= Ab). Concentrated DNA solutions required 
to saturate the drug at 37°C in 0.2 M KCl absorb light 
strongly, probably due to scattering and introduce error 
in the determination of absorbance. 
From these values, the fraction of DNA-bound inhibitor 
(b) was calculated using equation (1). 
( 1 ) 
The molar ratio of inhibitor bound to DNA per nucleo-
tide (rb) as well as the concentration of "free," unbound 
r inhibitor (If) and bound inhibitor (Ib) were calculated using 
' 
equations (2) and (3), respectively. 
(2) 
(3) 
Then, the values of the apparent dissociation constant 
(kapp) and the maximum number of binding sites per DNA 
nucleotide (n) were obtained from the slopes and intercepts 
of plots constructed according to Scatchard (1949) and 
described by equation (4). 
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(4) 
5. Enzymatic Activity Assays 
In this work, enzymatic activity was always determined 
by measuring the incorporation of radioactivity from a 
radioactively labelled nucleoside triphosphate substrate 
into material insoluble in 5% trichloroacetic acid.· 
A typical reaction mixture consisted of a buffer 
solution, r2 DNA, RNA polymerase, the inhibitors (if any) 
and an equ.imolar mixture of the four nucleoside triphosphates 
~ith one, or more, of them radioactively labelled. These 
components were transferred with fixed needle Hamilton 
syringes into 10 x 75 mm disposable glass test tubes fitted 
loosely with plastic caps. (A Hamilton syringe fitted with 
an Oxford pipette disposable plastic tip was used for 
transferring the r 2 .DNA in order to avoid any nicking or 
breaking due to shear.) The test tubes had been kept at 
140°C for at least 48 hrs prior to use, in order to 
inactivate any contaminating ribonuclease activity. The 
same treatment was given to all glassware used to prepare 
assay buffers. Alternatively, containers were washed with 
a dilute solution of NaOH which destroys ribonuclease. 
Care was exercised to handle all equipment with plastic 
disposable gloves. The two main types of experiments 
conducted under these conditions are described below. 
a. Experiments Not Involving Rifampicin 
In experiments designed to study the effect of 
inhibitor on the rate of RNA synthesis in the presence of 
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a constant amount of DNA, the concentration of T2 DNA was 
30 ~~· This concentration was chosen so as to correspond 
to the minimum amount of DNA required in order to saturate 
the activity of 4 ~g of RNA polymerase under the conditions 
described below. This amount of DNA corresponds to a molar 
ratio of enzyme to T2 DNA initiation sites of the order of 
25 since the number of such sites per T4 DNA molecule is 
approximately 22 (Bautz and Bautz, 1970). 
In these experiments, 37 ~1 of 2.5X concentrated assay 
buffer A was mixed with the appropriate amounts of T2 DNA 
to yield final concentrations of 0.2 M KCl, 0.04 ~ Tris-HCl, 
0.01 M MgC1 2 , 0.1 mM EDTA, 0.32 mM K2HP04 , 0.1 mM dithio-
threitol, 0.4 mg/ml BSA, at pH 7.9 and 25°C. Inhibitor 
(if any) was added and the solution was brought up to 84 ~1 
wi'th deionized distilled water at 0-5°C. The mixture was 
transferred to a 37°C bath and, after 6 min, the enzyme 
(4 ~g) was added in 8 ~1 of a solution consisting of 3 ~1 
of assay buffer A (concentrated 2.5 times}, 3 ~1 of 
deionized water and 2 ~1 of the commercial enzyme solution. 
Seven minutes later the reaction was initiated by the rapid 
addition of a solution consisting of 0.8 mM each of ATP, GTP 
and CTP and 0.4 mM 8-[ 3H]-U!P (specific activity 0.010 
~Ci/nmol or 0.1 ~Ci/nmol depending upon the experiment) 
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in 8 vl of water adjusted to pH 7.9 with 1.0 M Tris-base. 
The reaction was allowed to proceed for exactly 7.0 mfn 
and then it was terminated through the rapid addition of 
0.5 ml of an ice cold solution containing 0.1 M sodium 
pyrophosphate and 2 mM UTP (or 0.02 M ATP or GTP for the 
initiation experiments) followed by 0.5 ml of ice cold 11% 
TCA- 1.0 M KCl - 0.01 M sodium pyrophosphate solution. 
After mixing and standing in ice for at least 10 min 
the insoluble material was collected by filtration through 
a Whatman (2.4 em diam~ter) GF/C filter. The filter was 
rinsed with 15 ml of ice cold 5% TCA- 1.0 M KCl - 0.01 M 
sodium pyrophosphate solution followed by 30 ml of 95% 
ethanol, was dried under suction and at 105°C for 3 min 
and, finally, counted under 0.4% 2,5-diphenyloxazole in 
toluene solution in the Beckman LS counter. 
Experiments designed to measure the inhibition of 
0 y- 32 P-incorporation, which is a measure of the inhibition 
of RNA chain initiation, were conducted exactly as 
described above, with y- 32P-labelled ATP or GTP (specific 
activity 1.0 vCi/nmol) and final nucleoside triphosphate 
concentration 0.2 mM in ATP, GTP, CTP, and 8-[ 3H]-UTP 
{specific activity 0.01 ~Ci/nmol). 
A specific washing procedure for experiments involving 
incorporation of 32 P was employed in order to decrease the 
background of unincorporated radioactivity. The filters 
were washed with 100 ml of the TCA-KCl-pyrophosphate solution 
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mentioned above followed by 60 ml of 80% ethanol ~nd were 
subsequently stirred before drying and counting. Identical 
3H-cpm were recovered after this treatment indicating 'that 
product is not lost. 
Simultaneous counting of samples containing both 32p 
and 3H was effected with the Beckman Isoset system with a 
gain setting of 3.0. Under these conditions no Tritium 
spill-over could be detected in the 32 P-above- 3H wi~dow, 
while less than 2% spill-over from 32P was detectable in 
the 3H-below- 14c window. 
b. Experiments Involving Rifampicin 
As described in the Introduction, these experiments 
were designed in order to measure the effects of various 
inhibitors on the rate constants governing the initiation 
steps of RNA synthesis. All experiments were conducted 
in buffer B consisting of 0.04 M Tris-HCl, 0.02 M MgC1 2, 
0.1 mM EDTA, 0.32 mM K2HP0 4 , 0.1 mM dithiothreitol, 0.8 
mg/ml BSA pH 7.9 at 25°C (Mangel and Chamberlin, 1974a). 
Experiments measuring the rate of RNA synthesis as 
a function of preincubation time were conducted as follows. 
The buffer solution (37 ~1) at 2.5 times the final desired 
concentration was mixed with the desired amount of inhibitor, 
template {50 ~M T2 DNA) and deionized water to a final 
volume of 72 ~1. After standing in ice for at least 10 
min, the enzyme (4 ~g) was added in 8 ~1 of a solution 
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consisting of 3 pl buffer B (2.5 times concentrated), 3 ~1 
deionized water and 2 ul of the commercial enzyme prepara-
tion. After 10 more minutes at 0°C the test tube containing 
the above mixture was transferred into a 30°C bath for the 
desired time. The reaction was then initiated by the rapid 
addition of an XTP-rifampicin mixture in 20 ul 0.04 M Tris-
HCl pH 7.9. This mixture had been equilibrated at room 
temperature and was prepared so as to result in final assay 
concentrations of 30 pg/ml rifampicin and 0.4 mM XTP 
(specific activity 0.10 uCi/nmol 8-[ 3H]-ATP). For the 
control reaction rifampicin was omitted and an equal volume 
of deionized water was used instead. After exactly 1.5 min 
of incubation at 30°C the reaction was terminated and each 
mixture was processed as described under section Sa. 
In experiments designed to measure the rate of RNA 
synthesis as a function of rifampicin concentration the 
buffer solution, the inhibitor, the DNA (90 uM) and 
deionized water were mixed in the same manner as described 
above. Then the enzyme (2 ug in 8 ul) was added and the 
mixture was preincubated for 7 min at 30°C. The reaction 
was initiated by the addition of an XTP-rifampicin mixture 
prepared so as to result in 0.4 mM XTP (specific activity 
0.10 uCi/nmol 8-[ 3H]-ATP) while providing the_ desired final 
rifampicin concentration. After 1.5 min at 30°C the 
reaction was terminated and each mixture was processed as 
described above. In these experiments the enzyme to T2 DNA 
initiation sites ratio was either 15 or 40, assuming that 
65% of the protein is active holoenzyme. This ratio is 
higher than the ratio of 1 used by Mangel and Chamberlin 
(1974) with T7 DNA. The use of excess enzyme ensures that 
the total number of initiation sites participates in 
product formation. 
In all experiments measuring incorporation of radio-
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activity into 5% TCA insoluble product, background values 
were determined by treating identically a complete reaction 
mixture not containing enzyme. Background values were less 
than 200 cpm in experiments involving 3H and less than 
700 cpm in experiments using 32p. 
RESULTS 
1. The Binding of Phenanthridines to DNA 
The binding of ethidium bromide and a number of 
structural analogs of this phenanthridine to DNA has been 
extensively studied (Kindelis, 1976; Waring, 1974). 
However, in order to obtain a quantitative measure 
of the distribution of the drug between the template-
bound and the free forms under the ionic environment ·and 
temperature conditions of the assays used for determining 
rates of RNA synthesis, the binding parameters for each 
drug must be determined under those conditions. 
However, three of the compounds shown to inhibit 
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RNA synthesis exhibited complex spectroscopic characteristies 
(Kindelis, personal communication). The reasons for such 
a behaviour could be attributed to the fact that complexes 
of DMNC with DNA were only partially soluble, MMPB was not 
completely soluble at the desired concentrations and DDEB 
appeared to aggregate at high concentrations. 
Binding experiments leading to the calculations of 
rb (the molar ratio of drug bound per DNA nucleotide) and 
If (the concentration of free drug) were conducted as 
described under the Methods. The values of the apparent 
dissociation constant (kapp) and the maximum number of 
binding sites per DNA nucleotide (n) were obtained from 
the slopes and intercepts of plots constructed according 
to Scatchard (1949) and described by the equation 
= 
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(4) 
The Scatchard plots for EM, MAPEC, OEMS and DMEB are 
shown in Figure la and b. The values of kapp and n, 
calculated for each drug are listed in Table 1. Comparison 
of the values in Table 1 and inspection of the plots in 
Figure 1 allow the following conclusions to be drawn: 
a) The intrinsic affinities for DNA of all four drugs 
as well as the corresponding number of binding sites are 
similar in magnitude. 
b) Only one type of binding, i.e., binding to primary 
sites in which the bound drug molecules are intercalated 
between neighbouring base pairs is evident. Drug bound 
weakly to secondary sites on the outside of the DNA helix 
is not present to an appreciable extent as indicated by 
the linearity of the Scatchard plots and the magnitude of 
n. This binding behaviour is expected at relatively high 
(0.2 M KCl) ionic strengths (Wariny, 1965b). 
Table 1. Chemical Structure and Properties of some Phenanthridinium Derivatives 
Em ax 
kdiss 
Systematic Name Abbreviation MW (llM) n 
3,8-diamino-5-ethyl-6-phenyl- EM 394 5600479 18.9 0.19 
phenanthridinium Bromide 
3,8-diamino-5-ethyl-6-methyl- DMEB 332 3900463 32.2 0.19 
phenanthridinium Bromide 
3,8-diamino-6-ethyl-5-methyl- DEMB 332 4700463 38.1 0.18 
phenanthridinium Bromide 
3,8-diamino-5,6-diethyl- DDEB 346 4100463 phenanthridinium Bromide 
3,8-diamino-5-methyl-6-nonyl- DMNC 386 4900467 
phenanthridinium Chloride 
8-amino-6-p-aminophenyl-5-ethyl- MAPEC 349 4800431 32.4 0.17 phenanthridinium Chloride 
8-amino-5-methyl-6-phenyl- MMPB 365 3650430 
phenanthridinium Bromide 
8 3 
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Figure 1. Scatchard plots for some phenanthridines. 
a) EB, -t-; MAPEC, -!-. b) DMEB, -•-; DEMB, -6-. 
Experiments were conducted at 37°C in binding buffer 
(0.2 M KCl, 0.04 M Tris-HCl, 0.01 M MgC1 2 , 0.1 mM 
EDTA, 0.32 mM K2HP0 4 , pH 7.9 at 25°C) with calf-
thymus DNA as described under Methods. The amount of 
the DNA was varied between zero and 6 mM while the 
concentration of each phenanthridine was chosen so 
as to yield an absorbance reading of 1.0 at the maxi-
mum wavelength. 
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2. The Effect of Template Concentration on Inhibition 
~ Waring (1965a) has demonstrated that ethidium bromide 
~ 
f inhibits RNA synthesis competitively with the template, by 
determining the level of enzymatic activity as a function 
of template concentration in the absence and in the presence 
of a constant amount of inhibitor. In the present study, 
similar experiments were performed with MAPEC, DEMB, and 
DMEB, the structural analogs of ethidium bromide, and the 
data were plotted as activity-l ~· [DNA]- 1. In each of 
the double reciprocal plots shown in Figure 2a, b and c, 
the lines for the inhibited and uninhibited reactions are 
crossing over on the activity axis indicating that the 
inhibitory effect of the drug would be completely alleviated 
at infinite DNA concentrations. It may also be noted that 
in the presence of inhibitor the double reciprocal plots 
shown ip Figure 2a, b and c are curvilinear, a character-
istic which becomes more pronounced at the higher drug 
concentrations. This apparently abnormal behaviour, whicb 
has previously been noted by Waring (1965a) will be 
discussed in a later section. 
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Figure 2. The effect of template concentration on the rate 
of RNA synthesis either i~ the absence of inhibitor, -•-, 
or in the presence of the following amounts of inhibitor: 
a) 14.0 uM MAPEC; b) 11.0 u~ DMEB; and c) 15.0 uM OEMS. 
Experiments were conducted in 0.1 ml of assay buffer A 
containing 0.8 mM each of ATP, GTP and CTP, 0.4 mM 8-[3H]-
UTP (0. 1 uCi/nmol), 4 ug RNA polymerase and increasing. 
amounts of r 2 DNA. Reaction time was 7 min at 37°C. 
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3. The Effect of Drug Concentration on Enzymatic 
Activity 
48 
J In order to study in more detail the inhibitory effect 
of the phenanthridines on RNA synthesis, experiments were 
performed in which increasing amounts of drug were mixed 
J 
r with constant amounts of DNA, enzyme and substrate [XTP] p 
~ and assayed for RNA polymerase activity. 
i ~ The phenanthridinium derivatives studied may be 
J 
! 
characterized as strong inhibitors of RNA polymerase~ since t 
1-~ inhibitor concentrations as low as 50 uM were found to 
l ~ 
f ~ 
r 
cause complete inhibition of RNA synthesis. Plots of the 
data as activity (per cent) Yi· inhibitor concentration 
(Figure 3a and b) reveal that the activity curves of all 
compounds studied displayed the same overall shape. 
Enzymatic activity gradually decreases with increasing 
concentration of inhibitor up to a certain point where a 
sharp decline in activity is observed with a small increase 
in inhibitor concentration, followed by a much slower 
further decrease in activity which eventually reaches the 
zero (per cent) level at very high inhibitor concentrations 
(above 50 u~). These qualitative similarities seem to 
suggest a mechanism of inhibitory action common to all 
drugs. 
However, important quantitative differences are also 
evident. Ethidium bromide, which causes 40% inhibition at 
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Figure 3. The effect of phenanthridine concentration on the 
rate of RNA synthesis relative to the uninhibited reaction. 
The maximum activity (100%} corresponds to the incorpora-
tion of 2.5 x 104 cpm into product insoluble into 5% TCA. 
Reactions were conducted in 0.1 ml of assay buffer A con-
taining 0.8 m~ each of ATP, GTP, and CTP, 0.4 m~ 8-[ 3 ~]-
UTP (0.01 ~Ci/nmol}, 4 ~g RNA polymerase and 30 ~M T2 DNA 
for 7 min at 37°C. 
a} Each bar represents the standard deviation of 
the mean of twelve determinations for EB, -•-; MAPEC, -A-; 
DMEB, -o-, DEMB, -•-. Standard deviation of the mean (a) 
was calculated using the formula 
where x is the experimental value and N is the number of 
values. 
b) The experimental points are less accurate than 
those of Figure 7a due to the fact that complexes of DMNC, 
-o-, with DNA were partly soluble in the assay mixture; 
MMPB, -1-, was not completely soluble at the desired 
concentration; DDEB, -v-, appears to aggregate at high 
concentrations. 
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(b) 
30 
a concentration of only 4.5 u~ as compared with DEMB, for 
which 14.5 uM are required to reach the same level of 
inhibition, appears as the strongest inhibitor. Table 2 
lists the drug concentration for which 40% inhibition is 
reached. The values are determined from the plots in 
Figure 3a and b. It may be observed that maximum inhibitory 
capacity appears to be associated with the presence of 
large hydrophobic groups at position ~of the phenan-
thridinium ring. The effect of the relatively large, 
hydrophobic phenyl or nonyl groups, in the case of EB and 
DMNC respectively, is particularly apparent if the 
inhibitory effectiveness of these two drugs is compared 
with that of ·DDEB, DMEB or DEMB, i.e., compounds that carry 
~. the smaller methyl or ethyl groups at the same position. 
Only 4.5 uM and 7.0 uM of EB and DMNC respectively are 
required for 40% inhibition, which is two to three times 
less than the concentrations of DDEB (12.5 uM), DMEB 
(13.5 uM) or DEMB ( 14. 5 uM) required for the same inhibitory 
effect. 
The inhibitory effectiveness of MMPB relative to EB 
can only be tentatively assessed due to the apparent 
solubility problem associated with the former compound (see 
legend to Figure 3b}. Specifically, it appears that the 
absence of an amino group at position 1 of the molecule 
renders the compound a much weaker inhibitor. Again much 
less EB (4.5 uM} is required than MMPB (11.0 uM) in order 
Table 2. Comparison of the Pharmacologic and Inhibitory 
Effectiveness of some Phenanthridines 
Trypanocidal Concentration 
Activity* Resulting in 40% 
Compound (Dimidium = 1) Inhibition (ll!1) 
EB 10.00 4.5 
DMNC Active** 7.0 
MAPEC 0.50 9.3 
MMPB 11.0 
DDEB 0.22 12.5 
DMEB 0.12 13.5 
DEMB 0.10 14.5 
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*Data compiled from the Median Curative Dose determinations 
of Woolfe, G., (1956a, b). 
**Active indicates trypanocidal activity below 0.10 relative 
to dimidium. 
54 
to inhibit RNA synthesis to the same extent (Table 2). 
The relative inhibitory strength of EB and MAPEC, another 
derivative lacking the amino group at position 1 but 
carrying a second amino group at the para position of the 
phenyl substituent, seems to support the same conclusion, 
i.e., the absence of the amino group at position 1 renders 
a compound a weaker inhibitor than ethidium bromide. 
\ 
4. The Effect of DNA~bound Inhibitor on RHA 
Synthesis 
55 
Ethidium bromide has been shown to inhibit RNA 
synthesis by inactivating template molecules, not enzyme 
molecules, as a result of the association of the drug with 
template (Waring, 1965). Consequently, the active 
ethidium bromide as an inhibitor of RNA synthesis 
is the DNA-bound form of the drug. An appropriate means 
of expressing quantitatively the concentration of the 
active form of ethidium is in terms of the ratio of drug 
· m~lecules bound per DNA nucleotide (rb). This ratio, 
however, does not depend linearly on the total drug 
concentration (see equation 5, section 7 of Results), a 
factor which may become particularly important in compara-
tive studies of the inhibitory effectiveness of the struc-
tural analogs of ethidium bromide which have similar, but 
not identical affinities for the DNA template. 
In order to establish that the differential inhibitory 
capacity of the phenanthridines is not simply the result 
of their different affinities for the DNA template, the 
dependence of RNA polymerase activity was determined as a 
function of rb of each drug. 
The values of rb were calculated for each drug using 
equation 4, section 1 of Results, and were subsequently 
employed in plots of RNA polymerase activity (%) as a 
function of rb. In Figure 4, the enzymatic activity appears 
to depend linearly on rb in the range between 90% and 15% 
with either ethidium bromide or its derivatives as the 
inhibitor. A similar observation regarding the linear 
dependence of RNA polymerase activity on the rb of 
ethidium bromide has also been made by Waring (1965a). 
56 
The compounds included in Figure 4 exhibit clear 
differences in their inhibitory capacity against RNA poly-
merase. Comparison of the values of enzymatic activity 
remaining at a value of rb = 0.04 reveals that EB is the 
strongest inhibitor among these compounds, effecting a 
54% decrease in enzymatic activity, while at the same value 
of rb MAPEC, DEMB and DMEB decrease the activity of RNA 
polymerase by 49%, 26% and 17% respectively (Table 3). 
These results indicate that identical numbers of bound 
inhibitor molecules per molecule of DNA have different 
inhibotory effects on the ability of RNA polymerase to 
utilize this DNA as a template for RNA synthesis. Conse-
quently, the inhibitory effectiveness of these phenanthri-
dines is determined not only by the affinity of each compound 
for the template, but also by the specific structure of 
each intercalated inhibitor molecule. 
Table 3 also lists the values of rb of each drug 
which result in total inhibition of RNA synthesis (r 10) as 
obtained by ~xtrapolating the linear portion of the curves 
in Figure 4 to zero activity. From these values it would 
appear that on the average, intercalation of one inhibitor 
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Figure 4. Dependence of the rate of RNA synthesis on 
the concentration of the template-bound form of the 
inhibitor. EB, -e-; MAPEC, -A-; DMEB, -o-; DEMB, -•-. 
Plots constructed on the basis of the inhibition data 
shown in Figure 3a. 
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Comparison of the Inhibitory Effectiveness of 
the Template-Bound Forms of the Various 
Inhibitors 
Decrease in 
rb, 40% r I, 100% Activity (%) Inhibitor at rb = 0.04 
EB 0.032 0.068 54 
MAPEC 0.036 0.058 49 
DEMB 0.048 0.077 26 
DMEB 0. 051 0.080 17 
40% is the ratio of bound inhibitor per DNA nucleotide 
required for 40% inhibition. 
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100% is the ratio of bound inhibitor per DNA nucleotide 
that effects total inhibition. r1, 100% is obtained 
by extrapolating the linear portion of the curves shown 
in Figure 4 to zero activity (%). 
molecule per seven base pairs can completely abolish the 
template properties of the DNA when measured by this 
method. The significance of this observation with respect 
to the mechanism of template inactivation will become 
apparent in a later section • 
• 
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5. Ethidium Bromide Analogs Limit the Number of 
RNA Molecules that can be Initiated without 
Interfering Significantly with the Elongation 
of Initiated Chains 
61 
One method for determining whether a given compound 
inhibits RNA synthesis by interfering with RNA chain 
initiation and/or chain elongation is to study the incorpora-
tion of radioactivity from two different substrates 
simultaneously, i.e., the incorporation of a y-[ 32 P] ·labelled 
purine triphosphate nucleoside and a [ 3H] or [ 14c] labelled 
nucleotide triphosphate as described by Maitra ~ !l· (1967). 
In order to determine whether the structural analogs 
of ethidium bromide inhibit one or both steps involved in 
RNA chain synthesis, the simultaneous incorporation of 
radioactivity from a y-[ 32 P]-ATP - [ 3H]-UTP and a y-[ 32 P]-
GTP - [ 3H]-UTP system was measured as a function of inhibitor 
concentration. The results are shown in Figure 5a, b, c and 
d. The decline in product formation in the presence of 
increasing amounts of inhibitor (as evidenced by [ 3H] 
incorporation) loosely parallels the decline in the number 
of chains being initiated with either ATP (as evidenced by 
[ 32 P] incorporation from y-[ 32 P]-ATP) or GTP (as evidenced 
by [ 32 P] incorporation from y-[ 32P]-GTP) as the first 
nucleotide. This behaviour indicates that ethidium bromide 
analogs inhibit RNA synthesis mainly by limiting the number 
f 62 
J f of chains that can be initiated rather than by reducing the 
• 
f growth rate of initiated chains. 
; , 
Using this method with circular DNA from Pseudomonas 
phage 2 as template, Richardson (1973a) found that ethidium 
bromide inhibits RNA chain initiation without interfering 
with chain elongation. However, with a linear template, 
ethidium bromide appeared to inhibit to a significant extent 
chain elongation as well, especially at high inhibitor 
concentrations. 
The extent to which each drug inhibits (in addition to 
its primary effect on chain initiation) chain elongation is 
quantitatively depicted in the insets to Figure Sa, b, c 
and d. Theoretically the ratio [ 3H]/[ 32 P] is a measure of 
the degree of polymerization of the average product chain. 
In the extreme case characterized by inhibition of initiation 
and the absence·of any effect of the inhibitor on the rate 
of chain elongation, the degree of polymerization of the 
p~oduct should remain constant with increasing inhibitor 
concentration, i.e., the [ 3H]/[ 32 P] ratio should exhibit a 
slope of zero. In the case where inhibition is exerted 
only at the level of chain elongation, a line with a 
negative slope should be obtained. The slope of this line 
should be equal to that of the activity ~· inhibitor 
concentration curve. Accordingly, compounds inhibiting 
both st~ps of RNA synthesis_ would be expected to yield lines 
of negative slopes, the steepness of which would be a 
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Figure 5. Inhibition of the rate of total RNA synthesis 
and the rate of RNA chain initiation. [ 3H]-UMP incor-
poration, -o-; y-[ 32 P]-ATP incorporation, -a-; y-[ 32 P]-
GTP incorporation, -!-; for a) EB; b) MAPEC; c) DMEB 
and d) DEMB. In each case, the ratio of %[ 3H] vs • 
...... 
%[ 32 P] incorporation, -o-, was calculated using the 
formula 
= 
This formula is used because, in the absence of inhibitor, 
four RNA molecules are initiated with ATP for every mole-
cule initiated with GTP as determined by the molar ratio 
of A-starters to G-starters. This ratio was calculated 
from these data under conditions of identical UMP incor-
poration. 2.5 x 104 cpm of [ 3H]-UMP, 5 x 103 cpm of 
y-[ 32 P]-ATP and 2 x 103 cpm of y-( 32 P]-GTP were incorporate 
in the absence of inhibitor. Each bracket represents 
standard deviation of the mean of six determinations. The 
DNA concentration was 30 uM. The specific activity of 
y-[ 32 P]-labelled nucleotides was 1.0 uCi/nmo1 and that of 
8-[ 3H]-UTP was 0.01 uCi/nmol. 
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measure of the relative degree of inhibition of the initiation 
and elongation steps. 
The two strongest inhibitors, EB and MAPEC, appear 
to have, in addition to their major effect against RNA 
chain initiation, a minor effect on the rate of chain 
elongation as well. The negative slope observed in the 
inset to Figure Sa indicates that with a linear DNA such 
as T2 DNA as template high concentrations of ethidium bromide 
decrease to some extent the rate of elongation although the 
main effect is still exerted on the number of chains that 
can be initiated. This result is in agreement with previous 
reports (Richardson, 1973}. MAPEC appears to inhibit chain 
elongation to a lesser degree than ethidium bromide as 
indicated by the reduced slope of the curve in the inset 
to Figure Sb. On the other hand, both DMEB and DEMB appear 
to behave essentially as initiation inhibitors and have 
a very small, if any, effect on RNA chain elongation 
(Figure Sc and d). DMEB and DEMB may therefore be used 
most profitably in studies of the mechanism of inhibition 
of RNA synthesis by chain initiation inhibitors. 
Some information, albeit tentative, about the relative 
number of RNA molecules starting with ATP ~' GTP may be 
obtained from the activity curves in Figure Sa, b, c and d. 
Under the conditions of these experiments a ratio of A to G 
starters of A was observed. This ratio which depends 
largely on experimental conditions is within the range of 
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1-6 observed with holoenzyme and r4 DNA as template 
(Maitra ~ !l·, 1967}. Under experimental conditions 
different from those used here, a ratio of 1.3 was obtained 
with T2 DNA as template (Maitra ~ !l·• 1967}. It may be 
observed that in every case the incorporation of radio-
activity from y-( 32 P]-GTP declines faster with increasing 
inhibitor concentration than the incorporation from y-( 32 P]-
ATP. It thus appears as if the initiation of RNA molecules 
which carry GTP as their terminal 5' nucleotide (G-starters} 
is inhibited more effectively than RNA molecules with an 
ATP as their 5' terminal nucleotide (A-starters}. This 
finding, which pertains to a linear DNA, is in contrast to 
a previous report (Richardson, 1973) that A-starters are 
inhibited by EB more effectively than G-starters when a 
circular DNA templlte from Pseudomonas phage£ is used. 
It is possible that the physical state of the template is 
responsible for the preferential inhibition of A-starters 
by ethidium bromide when the superhelical PM2 DNA is used 
as template. However, the relatively high experimental 
error associated with measurements of [ 32 P] incorporation 
in experiments of this type requires a cautious interpreta-
tion of small differences in the exact values of the 
activity curves as those observed in Figure 5a, b, c and d. 
6. The Effect of Ethidium Bromide and DEMB on the 
Steps of RNA Chain Initiation 
70 
Inhibitors of DNA-dependent RNA polymerase may be 
expected to exert their effect at one or more of the various 
steps involved in RNA synthesis. Inhibition may be the 
result of an alteration in either the rate or the number 
of enzyme molecules traversing any given step or .a combina-
tion of the two effects. In the previous section it was 
shown that EB and DEMB inhibit RNA synthesis by limiting 
the number of enzyme molecules that can form the first 
phosphodiester bond of the product without significantly 
affecting the rate of polymerization of the initiated 
chains. This limitation in the number of chains growing 
in the presence of EB or DEMB results from the inhibition 
of a step prior to the formation of the first phospho-
diester bond and may, in turn, reflect an effect of the 
inhibitor on the rate and/or the number of enzyme molecules 
traversing that prior step or steps. 
As described in the Introduction, two major steps 
are presently recognized in the process of RNA chain 
initiation by DNA-dependent RNA polymerase. Methods which 
allow the independent determination of the number and the 
rate of enzyme molecules which are traversing each of these 
steps have also been developed (Mangel and Chamberlin, 1974a 
and c). These methods when used in the absence and in the 
r 
r 
' 
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presence of an inhibitor, such as ethidium bromide or DEMB, 
which have been shown not to inhibit chain elongation 
appreciably, can provide information concerning the effect 
of the inhibitor on either one or both of these parameters. 
a. Ethidium Bromide and DEMB do not Affect 
the Rate of the Second Initiation Step 
The effect of the two intercalating drugs ethidium 
bromide and DEMB on the rate and the number of RNA polymerase 
molecules traversing the second initiation step (see 
Introduction) was studied by determining the level of 
enzymatic activity as a function of rifampicin concentration 
in the presence and in the absence of these inhibitors.* 
The results of these experiments were analyzed according to 
the equation described by Chamberlin (1974): 
= 
k2 
· [rifampicin] 
C* k* 
where CT and C* are the total binary RNA polymerase-DNA 
complex concentration and the concentration of binary 
complexes able to initiate an RNA chain respectively; and k2 
*Heretoforth the terms inhibitor, inhibited reaction, etc., 
will be reserved only for intercalating compounds such as 
EM, DEMB, actinomycin D, etc. Rifampicin, although a strong 
inhibitor of RNA polymerase in itself, is merely being used 
as a tool in these methods and will always be designated by 
its full name. 
and k* are the rate constants for rifampicin attack on 
binary complexes and RNA chain initiation respectively. 
Since, under our experimental conditions, the measured 
rates in the presence and the absence of inhibitor (v and 
Vmax respectively) are proportional to the concentration 
of the complexes, one can therefore write: 
CT - C* 
C* 
= 
vmax - v 
v 
= [rifampicin] 
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The results plotted in each case as the ratio of the rate 
of RNA synthesis without rifampicin (Vmax), divided by the 
rate of RNA synthesis with rifampicin (v) ~· rifampicin 
concentration are shown in Figure 6. The slope of each 
line is a measure of the ratio of the rate constant of 
rifampicin attack on the enzyme over the rate constant of 
chain initiation through the second initiation step 
(Mangel and Chamberlin, 1974a). If we assume that the 
rate of rifampicin attack on the enzyme is the same in 
the presence as well as in the absence of inhibitor, then 
the slope of each line in Figure 6 is a measure of the 
rate constant of initiation through the second initiation 
step. The near identity of the slopes for the inhibited 
and uninhibited reactions indicates that the presence of 
either EB or DEMB has no effect on the rate constant of 
RNA polymerase molecules which proceed from their RS 
complexes to form the first phosphodiester bond. These 
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Figure 6. The dependence of the relative rate of RNA 
synthesis on rifampicin concentration. The rate of 
incorporation of radioactivity into product in the 
absence of both inhibitors and rifampicin (Vmax> was 
8.4 x 103 cpm. v is the rate of the reaction in the 
presence of rifampicin only, -•-; in the presence of 
rifampicin and an rb = 0.035 for EB, -a-; or in the 
presence of an rb = 0.50 for DEMB, -o-. Enzymatic 
activity wa~ assayed in 0.1 ml of assay buffer B 
containing 0.4 mM XTP (0. 1 vCi/nmol 8-[ 3H]-ATP), 2 vg 
RNA polymerase and 90 vM T2 DNA. Reaction conditions 
were 1.5 min at 30°C. The dotted line corresponds 
the theoretical curve that would be obtained using 
equation on page 72 in the presence of an inhibitor 
causing a 25% decrease in the rate of the control 
reaction (v) without affecting the number of active 
enzyme molecules. The slope of this curve relative 
to the control reaction is a measure of the sensi-
tivity of this method and demonstrates that all 
experimental curves in this Figure are parallel to 
one another within experimental error. 
to 
the 
j 
j 
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results also indicate that it is unlikely that either EB 
or DEMB Qffect the rate constant of rifampicin attack on 
RNA polymerase. Otherwise, these inhibitors would have 
to exert two equal and opposite effects on the rate 
constants governing initiation and rifampicin attack; 
i.e., two distinct reactions among different reactants 
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and sites on the enzyme. It is established that rifampicin 
attacks the site responsible for nucleotide binding (Wu and 
Goldwaith, 1969), while the DNA bound inhibitors would be 
thought to interfere with the template binding site of the 
enzyme. 
The intercept of each line on the Vmax/v axis of 
Figure 6 is, on the other hand, a measure of the maximum 
number of RNA polymerase molecules which are able to 
transform the RS complex to the rifampicin-resistant 
ternary complex (Mangel and Chamberlin, 1974a). In the 
presence of EB at an rb of 0.035 and DEMB at an rb of 
O.U50, the value for this intercept is 36y and 47% 
respectively of the value of the uninhibited reaction 
which indicates that both inhibitor·s strongly limit the 
number of enzyme molecules that can traverse the second 
initiation step. It should be emphasized, however, that 
the decrease in the Vmax/v intercept may be the result of 
either one of two possible causes. One possibility is 
that EB and DEMB may limit the number of enzyme molecules 
that can initiate directly by preventing the formation of 
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the RS complex. Alternatively, EB and DEMB may act by 
inhibiting a step prior to the formation of the RS complex. 
In either case, identical experimental results would be 
expected since the method employed merely measures the effect 
of the inhibitor on the maximum number of enzyme molecules 
that cBn form RS complexes irrespective of the origin of the 
effect. Further experimentation is therefore necessary in 
order to distinguish between these two possibilities. 
b. The Rate of RNA Polymerase Molecules 
Traversing the First Initiation Step 
is not Affected by the Presence of 
Either Ethidium Bromide or DEMB 
The effect of EB and DEMB on the rate and the number 
of RNA po1ymerase molecules traversing the first initiation 
step was studied by determining enzymatic activity as a 
function of pre-incubation time of the I complex in the 
presence and in the absence of rifampicin and one of the 
intercalating inhibitors (Methods). The results plotted 
as activity (cpm) ~· pre-incubation time are shown in 
Figure 7a and b. It is apparent that the curves in 
Figure 7a and b display the same overall shape; i.e., a 
rapid increase in the initial rate of incorporation of 
radioactivity is observed during the first two minutes of 
pre-incubation time, which is followed by a much more 
gradual increase of this rate at longer times. The control 
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Figure 7. The rate of RNA synthesis (cpm) as a 
function of pre-incubation time (sec) in the absence, 
-o-, and in the presence, -1-, of 30 ug/ml of 
rifampicin. a) in the presence of an rb = 0.035 
of EB with, -A-, or without, -~-, 30 ug/ml rifampicin; 
b) in the presence of an rb = 0.050 of DEMB with, 
-A-, or without, -~-, 30 ug/ml rifampicin; c) a 
composite plot of (a) and (b) showing the dependence 
of the logarithm of enzymatic activity (%) at infinite 
pre-incubation time, minus enzymatic activity (%) at 
time (t) ~· the pre-incubation time (t). Activity 
(%) is measured as the cpm incorporated in the presence 
of rifampicin divided by the cpm incorporated in its 
absence when no inhibitor was present, -o-, or when 
EB, -A-, or DEMB, -1-, was present. The activity 
levels corresponding to 160 sec of pre-incubation time 
are taken as the activity level at infinite time. 
Enzymatic activity was assayed in 0.1 ml buffer B 
containing 50 u~ T2 DNA and 40 ug/ml RNA polymerase 
as described under Methods. The nucleoside triphosphate 
concentration was 0.4 m~ (0.1 uCi/nmol 8-[ 3H]-ATP). 
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reaction, obtained in the absence of both rifampicin and 
inhibitor (see footnote on page 71 }, reaches maximum 
activity within the first minute of pre-incubation time, 
as expected (Mangel and Chamberlin, 1974c). 
The gradual rise in activity observed between two 
and thirty minutes of pre-incubation time appears to be 
faster in the presence of both DEMB and rifampicin (or, 
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to a lesser extent, in the presence of EB and rifampicin) 
than the rise in activity in the presence of rifampicin 
alone. As it will be discussed later, this apparent 
paradox may be due to the ability of the enzyme to overcome 
the inhibitory effect of DEMB (or EB) presumably by 
displacing at a very slow rate the intercalated drug from 
sites suitable for specific enzyme binding on the template. 
Figure 7c was constructed for the purpose of 
determining the half-life time of the I complex in the 
presence and in the absence of inhibitor. The incorporation 
of ·radioactivity (%) at infinite pre-incubation time (t~) 
minus the incorporation of radioactivity {%) at time (t) 
is shown in a logarithmic scale as a function of pre-
incubation time (t). (Incorporation of radioactivity 
per cent is the cpm incorporated in the presence of 
rifampicin divided by the cpm incorporated in its absence.) 
(Mangel and Chamberlin, l974c). The results obtained in 
the absence of inhibitor as well as those obtained in the 
presence of either DEMB or EB yield lines of similar slopes 
and intercepts indicating that the presence of the 
intercalated inhibitor has little effect on the rate of 
transformation of the I complex into the RS complex. 
On the other hand, the data shown in Figure 7a and 
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b reveal that addition of EB or DEMB together with rifam-
picin in the enzymatic assay mixture drastically decreases 
the level of incorporation of radioactivity by RNA polymerase 
far below the level obtained when rifampicin is added alone. 
These data indicate that both DEMB and EB have.a 
strong effect on the enzymatic activity of RNA polymerase 
above and beyond that exerted by rifampicin. The fact that 
the half-life time of the I complex is approximately the same 
in the presence of rifampicin, rifampicin-plus-DEMB and 
rifampicin-plus-ES indicates that neither DEMB nor EB 
significantly affect the rate at which RNA polymerase 
molecules can traverse the first initiation step. Therefore, 
the decreased level of activity in the presence of the 
inhibitor would have to be attributed to a decrease in the 
number of enzyme molecules that can form product. 
c. Evaluation of the Previous Results 
Ethidium bromide and DEMB have been found not to affect 
the rate constants of the elongation or the initiation steps 
although they strongly limit the number of enzyme molecules 
that can initiate a chain. Yet, EB and DEMB do not inhibit 
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each and every one of these steps, but they rather interfere 
with only one step and the effect is being carried over to 
the others. Two facts allow this conclusion to be drawn. 
First, concentrations of EB (0.035 rb) and DEMB (0.050 rb) 
that were shown to ~ause approximately 50% inhibition of 
the overall enzymatic activity are found to produce roughly 
the same degree of inhibition when each step is studied 
independently of the other. Second, the methods employed 
for the study of the effect of inhibitor on each initiation 
step merely measure the number of enzyme molecules that are 
traversing each step in the presence and in the absence of 
inhibitor, without providing any information as to which 
particular step or steps are inhibited. Inhibition of either 
the recognition or the elongation step, for example, could 
limit the number of enzyme molecules able to form product 
equally well. This fact, however, does not complicate the 
determination of the rate constants of the initiation and 
elongation steps which were specifically shown not to be 
affected by the presence of either EB or DEMB. It may 
therefore be concluded that EB and DEMB do not affect the 
rate constants of RNA polymerase traversing the initiation 
or the elongation steps, while at the same time, these 
compounds inhibit one of the steps involved in RNA synthesis. 
The one step inhibited could be either the recognition step 
or one of the initiation steps with the restriction that the 
primary mechanism of inhibition must exclude an effect of 
the inhibitor on the rate constants of the two initiation 
steps. Formation of the non-specific complex has already 
been shown not to be inhibited by EB (Richardson, 1973), 
and the rate of chain elongation was shown in section 5 
not to be significantly affected by either EB or DEMB. 
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7. -The Kinetics of Template Inactivation 
In the previous sections evidence was presented that 
oEMB exerts its inhibitory effect at a single step of RNA 
synthesis ·by interfering with the formation of an enzyme-
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DNA productive complex. However, DEMB may inhibit the 
formation of this complex through any one (or a combination) 
or two distinct, general mechanisms. On one hand, inter-
calation of the drug at a specific site of the template 
might distort the conformation of that site so that the 
enzyme would not be able to recognize the site and bind on 
it productively. In this case, the number of enzyme 
molecules able to form product in the presence of DEMB 
would be decreased although those enzyme molecules able to 
recognize the binding site would be expected to synthesize 
product at a rate unaffected by the presence of the inhibitor. 
On the other hand, the presence of drug at a specific site 
of the template might allow recognition by the enzyme to 
take place, albeit at a slower rate. In this case, the same 
number of enzyme molecules could be active in the presence 
of drug as in its absence, although in the presence of 
inhibitor these active enzyme molecules would be expected to 
form product at a reduced rate. 
In order to distinguish between these two alternative 
mechanisms, the effect of the inhibitor on the rate of 
formation of productive complexes must be determined 
independently of the effect of the inhibitor on the number 
of enzyme molecules which are able to form complexes of 
this type. 
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In 1970, Shih and Bonner demonstrated that computer 
fitting of experimental data of RNA polymerase activity as 
a function of the concentration of the DNA template yielded 
satisfactory fitting to an equation formally analogous to 
the Michaelis and Menten equation, provided that the enzyme 
concentration is kept constant. It was thus shown that the 
DNA template can kinetically be described as a substrate. 
Accordingly, and for the purpose of deriving kinetic 
equations, compounds believed to inhibit RNA synthesis by 
interacting only with the template (substrate) may be 
treated. as substrate inactivators, i.e., compounds that 
exert their inhibitory effect by lowering the effective 
concentration of the substrate. 
For simple enzymatic systems, inhibition via substrate 
ina~tivation has been described (Westley, 1969). However, 
quantitative treatment of the inactivation of a large 
template carrying many potential inhibitor binding sites 
would require a more carefully defined and, therefore, more 
complex description. Nevertheless, the quantitative 
description of such a system is greatly facilitated in view 
of the fact that compounds such as EB and actinomycin D 
have been shown to interfere.with the template function of 
the DNA but not to act directly on the enzyme. Accordingly, 
87 
a general hypothesis can be introduced specifying that in a 
oNA-drug inhibition system, a DNA-inhibitor (SI) complex may 
form while an enzyme-inhibitor (EI) complex is not formed. 
Then, the only additional assumptions to be made regarding 
this system should concern the properties of any possible 
ternary enzyme-substrate-inhibitor (ESI) complex. Thus, it 
may be assumed in turn, that {1) an ESI complex does not 
form; (2) an ESI complex does form but it cannot lead to 
product; (3) an ESI complex does form and does lead to 
product, but it does so as fast as the ES complex; or (4) 
that an ESI complex does form and does lead to product, 
but it does so at a rate different than that of the ES 
complex. For each of these cases, equations can be derived 
describing the dependence of enzymatic activity on the 
concentration of DNA as shown in the Appendix. In the 
derivation of these equations it is assumed that all 
complex formations preceding the chain elongation are 
rapid with respect to the elongation step, in agreement 
with all previous experimental observations. These equa-
tions predict that double reciprocal plots of RNA polymerase 
activity~· substrate concentration (DNA), constructed on 
the basis of experimental points obtained in the presence 
of a constant rb of inhibitor, should produce straight lines 
with intercepts on both axes characteristic of the mechanism 
of inhibition. 
In order to test the suitability of the equations 
describing quantitatively the effect of a rate inhibitor, 
actinomycin D was used, which has previously been shown to 
inhibit the rate of RNA chain elongation without affecting 
the number of chains that are being initiated (Hyman and 
Davidson, 1970). At the same time, in a similar but 
separate experiment, the kinetic behaviour of DEMB was 
tested using the method described below. 
Reaction mixtures were prepared in which the concen-
tration of DNA and that of the inhibitor (actinomycin D or 
DEMB) were adjusted so as to produce a constant ratio of 
bound drug to DNA nucleotide (rb) as the absolute values 
of concentration for both reagents were being increased. 
The amount of inhibitor mixed with a given amount of DNA 
in order to obtain a constant rb value was calculated 
using equation 5, which is directly derived from the 
Scatchard equation (equation 4, section 1 of the Results). 
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= (5) 
where [Io] is the concentration of the inhibitor to be 
mixed with the concentration of DNA, [DNA]. 
The binding parameters (kdiss and n) shown in Table 1 
were used for DEMB. For actinomycin D, the values reported 
by MUller and Crothers (1968) were used, adjusted according 
to Hyman and Davidson (1970), i.e., kdiss = 0.7 ~M. n = 
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0.110. (The binding parameters for actinomycin D were 
adjusted by taking into account the difference in the 
temperature between the experimental conditions reported by 
MUller and Crothers (1968) and those employed for the RNA 
polymerase assays.) 
The reaction mixtures used to assay RNA polymerase 
in the presence of DEMB or actinomycin D were processed as 
described previously (Methods) and the results were fitted 
into double reciprocal plots of activity~· substrate 
concentration [DNA] as shown in Figure 8. 
a. Inhibition by Actinomycin D 
In the presence of constant rb of actinomycin D, the 
intercept in Figure 8 on the reciprocal activity axis 
(Vint) appears to be lower than the Vint of the uninhibited 
reaction while the intercept on the reciprocal substrate 
axis (Kint) has the same value with the uninhibited reaction. 
This effect of the inhibitor on the values of Vint and Kint 
is predicted only for "rate inhibitors" as shown in Table 5. 
Therefore, among the various mechan~sms examined, actino-
mycjn D appears to fit only the mechanism predicted by 
equation 13 of the Appendix. This equation describes the 
kinetic behaviour of compounds that inhibit RNA synthesis 
by forming, with a productive enzyme-DNA complex, a ternary 
complex which cannot break down to form product. In other 
words, actinomycin D does not interfere with the number of 
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Figure 8. Double reciprocal plots of the dependence 
of the rate of RNA synthesis on the concentration of 
the template in the absence of inhibitor, -•-, and in 
the presence of DEMB at an rb = 0.055, -a-, or 
actinomycin D at an rb = 0.00085, -o-. Each experi-
mental point represents the mean of three determina-
tions; standard deviation of the mean was less than 9%. 
RNA polymerase (4 ~g) was assayed in 0.1 ml of buffer A 
containing 0.8 mM each of ATP, GTP and CTP and 0.4 mM 
8-[ 3H]-UTP (0. 1 ~Ci/nmol). Reactions were carried out 
for 7 min at 37°C as described under Methods. 
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enzyme molecules forming productive ES complexes, although 
it eventually combines with such a binary complex to form 
an inactive ternary ESI complex. Since actinomycin D 
inhibits the rate of chain elongation, the large majority 
of the ESI complexes must be formed between the inhibitor 
and the propagating binary complexes. Formation of the 
ESI complex forces the enzyme to terminate synthesis since 
the ESI complex cannot break down to form product. 
This model is in agreement with the well accepted 
view that actinomycin D inhibits RNA synthesis by decreasing 
the growth rate of the RNA chains without interfering with 
the number of RNA chains which are being initiated (Maitra 
et ~., 1967; Hyman and Davidson, 1970). 
b. Inhibition by DEMB 
In the presence of a constant rb of DEMB the intercept 
of the plot shown in Figure 8 on the reciprocal substrate 
axis (Kint) appears to be larger than the Kint of the 
uninhibited reaction, while the intercept on the reciprocal 
activity axis {Vint> has the same value with the uninhibited 
reaction. This effect of DEMB on the values of Kint and 
V. t is distinct from the pattern predicted for actinomycin D 1n 
by equation 13, but appears to be in general agreement with 
the pattern predicted by either equation 11 or equation 15 
of the Appendix (see also Table 4). 
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Table 4. Intercepts of Double Reciprocal Plots 
-
Type 
Intercept on 
Velocity Axis 
(Vint) 
Intercept on 
DNA Substrate 
Axis (Kint) 
---------------------------------------------~-----------
No Inhibition 1 1 
vmax K• 1 
Binding Site 1 1-rb 
Inactivation 
vmax K• 1 
11 Rate 11 Inhibition 1 1 
Vmax(l-rb) K• 1 
Mixed Binding 1 1-rb 
Site Inactivation 
Vmax 
--+ K3·rb K• 1 
Mixed Inhibition (1-rb) + K3·K•l.rb 1-rb 
- --+ K3·rb Vmax(l-rb) + V~ax·K3·rb K• 1 
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In order to distinguish graphically the pattern 
predicted by equation 11 from the pattern predicted by 
equation 15, the set of experimental data obtained in the 
presence of constant DNA concentration described in section 
4 was used. For experiments carried out in the presence 
of constant DNA concentrations equation 11, but not 
equation 15, predicts that a plot of 
vs. 1 
v 
should yield a straight line having an intercept of 1.0 
on the activity axis. Accordingly, if DEMB follows the 
mechanism corresponding to equation 11, then a plot con-
structed with the experimental data obtained in section 4 
should yield the pattern predicted by this equation. 
Nevertheless, when this plot is constructed, a curve of 
increasing slope instead of the expected straight line is 
obtained (Figure 9). However, when the same data are 
plotted as 
1 
vs. 
(where r 1 has the value shown in Table 3) a straight line 
is obtained with an intercept of approximately 1.0 on the 
activity axis (Figure 9). This latter plot is not the 
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Figure 9. A double reciprocal plot of the dependence 
of the rate of RNA synthesis on the ratio of DEMB bound 
per DNA nucleotide (1 - rb)' -o-; or the same ratio 
divided by the ratio of DEMB bound per DNA nucle~tide 
that results in complete inhibition (1 - rb/r 1), -1-. 
The graphs are replots of the data shown in Figure 4. 
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result of an arbitrary modification of equation 11. Rather, 
it results from a normalization which must be introduced in 
order to account for: a) the uncertainty regarding the exact 
size of the DNA length unit which is being inactivated by a 
single inhibitor molecule; b) the distribution of the inhi-
bitor on the specific promoter sites relative to the rest of 
the DNA molecule; and c) the fact that the usual expressions 
of rb in terms of inhibitor molecules bound per DNA nucleo-
tide, DNA base pair, DNA molecule, and so forth are p~rely 
arbitrary. 
As evidenced by the results shown in-Figure 9, intro-
duction of the value of r 1 into equation 11 can, at least 
mathematically, compensate for the lack of specific infor-
mation on these important aspects of the mechanism of 
template inactivation. Therefore, the value of r 1 must be 
introduced not only into equation 11, but also into equation 
16 as shown by equations 11 1 and 16 1 , respectively. 
Vmax K I 1 
= 1 + 1 . -- ( 11 I) 
v rb so 
1 
ri 
vmiiX Kl 1 1 + 1 ( 1 6 I ) = . --
v rb K1- K3 so 1- r Kl I 
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One additional test for the necessity of introducing 
r 1 into equations 11 and 16 is the fact that for the 
limiting case rb = r 1 , equations 11
1 and 16 1 yield v = o 
and for the case rb = o, the term containing the inhibitor. 
concentration disappears and equations 11 1 and 16 1 become 
identical with the equation for the uninhibited reaction. 
v 
Furthermore, plots of ~ax vs. 
1 -
1 for the phenanthridines 
rb 
rr 
shown in Table 3, also yield straight lines if, and only if, 
their corresponding r 1 values shown in Table 3 are intro-
duced into equation 11 1 (Figures not shown). 
K1- K3 Equations 11 1 and 16 1 differ only by the factor Kl 
which appears in the denominator of equation 16 1 • 
Accordingly, the two equations remain distinct only if the 
value of K3 is not negligible relative to the value of K1. 
For values of K3 which are less than 10% of K1 , equations 
11 1 and 16 1 may thus appear indistinguishable. Consequently, 
. . 
among the various mechanisms of inhibition, DEMB (and most 
probably by analogy EB, MAPEC and DEMB as well) appear to 
act by interfering with the formation of the first productive 
enzyme-DNA complex I. 
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8. Alternative Kinetic Methods 
In the previous section it was demonstrated that the 
reciprocal of RNA polymerase activity depends linearly on 
the reciprocal of DNA concentration in the absence of inhi-
bitor or in the presence of a constant ratio of inhibitor 
bound per DNA nucleotide (rb). However alternative kinetic 
methods have been extensively used and reported in the 
literature. In these methods the experimental data are 
also plotted in the form of the reciprocal of activity vs. 
the reciprocal of DNA concentration, but the experiments 
are conducted in the presence of either a constant amount 
of inhibitor or a constant ratio of inhibitor added per DNA 
nucleotide rather than a constant ratio of inhibitor bound 
per DNA nucleotide. 
In order to determine the suitability of these 
alternative kinetic methods for describing quantitatively 
the inhibition of RNA polymerase by intercalating drugs, 
experiments were conducted under conditions of constant 
drug concentration and constant added drug-to-DNA ratio 
and the results were presented in double reciprocal plots 
of activity~· DNA concentration as described below. 
a. Assaying RNA Polymerase in the Presence 
of a Constant Ratio of Inhibitor Added 
per DNA Nucleotid~ 
In the specific case of an inhibitor like ethidium 
, 
[ 
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bromide, DEMB or actinomycin D which were shown to act by 
altering the template properties of the DNA, the enzymatic 
activity must be assayed with an inhibitor-complexed 
template whose composition remains constant, as the para-
meter under study is varied. Constant template composition 
may readily be achieved experimentally when the template 
properties of chromatin for instance, which is a mixture 
of DNA template with inhibiting histone proteins, are 
being studied (Shih and Bonner, 1970; Cedar and Felse~feld, 
1973; Keshgegian and Furth, 1972). The high affinity of 
the histones for DNA apparently results to an approximately 
constant ratio of bound protein per DNA nucleotide as the 
concentrations of the DNA and protein components are 
increased in a fixed ratio. However when this method is 
adopted for the study of complexes of DNA with compounds 
having weaker binding than the histones, as the case is with 
EB and DEMB, use of increasing concentrations of a drug-DNA 
co~plex of a given added ratio would result in wide varia-
tions of rb within the range of DNA concentrations assayed 
for enzymatic activity. This point can readily be demon-
strated with the use of equation 5 of section 8 which 
allows calculation of the values of rb for any set of DNA 
and inhibitor concentrations based on the corresponding 
binding constants. 
When the concentration~ of DNA and actinomycin D in 
a constant ratio are varied over a ten fold range the values 
r 101 
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of rb remain almost unchanged. On the other hand, variation 
of the concentrations of DNA and DEMB over the same range 
results in a three fold change in the values of rb due to 
the fact that the affinity of DEMB for DNA is approximately 
40 times lower than that of actinomycin D. 
In order to investigate the relevance of this 
observation to the methods of assaying RNA polymerase 
activity in the presence of increasing amounts of inhibitor-
DNA complexes of a constant ratio, the concentrations of 
such complexes of DNA with actinomycin D and DEMB were 
varied over a ten fold range and assayed for enzymatic 
activity. The results shown in Figure 10 reveal the ex-
pected linear dependence between the reciprocal of 
enzymatic activity and the reciprocal of DNA concentration 
in the absence of inhibitor and in the presence of a 
constant added ratio of actinomycin D. On the other hand, 
severe deviations from linearity occur in the presence of 
a constant added ratio of DEMB which, as mentioned, has a 
much weaker affinity for the template than actinomycin D. 
In the case of DEMB, the values of ;·b change three fold 
over the DNA concentration range that was assayed for 
activity. ~his variation in rb produces a template of 
altered composition which, therefore, can support RNA syn-
thesis at varying effectiveness. 
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Figure 10. Double reciprocal plots of the rate of 
RNA synthesis as a function of template concentration 
in the absence of inhibitor, -t-, and in the presence 
of a constant ratio of DEMB added per DNA nucleotide 
(0.35}, -s-; or a constant ratio of actinomycin D 
added per DNA nucleotide (0.00115}, -o-. Reaction 
conditions were identical with those in the legend to 
Figure 8. 
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b. Assaying RNA Polymerase in the Presence 
of a Constant Amount of Inhibitor 
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Further demonstration of the effect of template 
composition on enzymatic activity can be made by assaying 
RNA polymerase at increasing DNA concentrations in the 
presence of a constant amount of inhibitor. In experiments 
of this type, the rb of the inhibitor continuously decreases 
with increasing concentration of DNA as it can readily be 
calculated again with the use of equation 5, section 1 of 
Results. As a result of this gradual decr~ase in rb, the 
double reciprocal plots shown in Figure 11 exhibit negative 
curvilinearity. The presence of curvilinearity in plots of 
this type has been reported previously although the reasons 
for this behaviour have not been discussed (Waring, 1965a). 
It may parenthetically be noted that the curves of 
the double reciprocal plots shown in Figure 11 appear to 
converge at the same point of maximum velocity despite the 
fact that at least in the case of actinomycin D which is an 
inhibitor of the rate of chain elongation, the enzyme may 
have not been expected to achieve maximum rate of transcrip-
tion. This unexpected behaviour however is apparently due 
to the fact that increasingly higher concentrations of DNA 
bind increasing amounts of drug and eventually ••dilute" the 
inhibitor to the point that inhibitor-free stretches of DNA 
are created for the enzyme to use for transcription. 
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Figure 11. Double reciprocal plots of the rate of RNA 
synthesis as a function of template concentration in 
the absence of inhibitor, -•-, and in the presence of 
a constant amount of 15 ~~ DEMB, -o-, or 0.0382 ~M 
actinomycin D, -e-. Reaction conditions were the same 
as those described in the legend to Figuri 8. 
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Clearly then, experiments conducted in the presence of 
either a fixed added ratio of inhibitor per DNA nucleotide 
or in the presence of a constant amount of inhibitor are 
inappropriate for describing the properties of the template 
for transcription. Instead, measurements should be carried 
out under conditions that produce a template of constant 
composition, i.e., at a constant bound inhibitor to DNA 
ratio. Only under such conditions the results would be 
informative as to whether a given template inactivator 
inhibits RNA synthesis by interfering with the rate terms 
of the reaction or the number of sites tha~ are available 
on the DNA for the binding of the enzyme in the manner 
described in section 7 of the Results. 
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DISCUSSION 
The structural analogs of ethidium bromide were found 
to be strong inhibitors of RNA synthesis catalyzed by DNA-
dependent RNA polymerase~ vitro (sections 1-6 of Results}. 
These compounds were shown to bind to the DNA-template and 
inhibit RNA synthesis linearly with their template-bound 
form within the limits of 10 to 90% inhibition. The 
inhibition of transcription by ethidium bromide and its 
structural analogs was then found to be the main result 
of a decrease in the number of RNA chains that can b~ 
initiated in the presence of inhibitor and, only to a minor 
extent, due to a reduction in the rate of elongation of the 
product chains (section 5}. Subsequent examination of the 
effect of EB and DEMB, two of the inhibitors under study, 
on each step of the process of RNA chain initiation revealed 
that the rate constants of RNA polymerase progressing 
through these steps are not altered by the presence of 
inhibitor although at the same time enzymatic activity is 
drastically decreased (section 6}. 
Although the use of rifampicin in the elucidation of 
the mechanism of initiation was developed with T7 DNA as a 
template, initial work on the effect of this inhibitor on 
RNA polymerase involved T2 DNA as template and comparable 
results were obtained with both templates (Sippel and 
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Hartmann, 1971). Moreover, studies with T4 DNA as templBte 
which, as stated in the Introduction, has identical proper-
ties with T2 DNA, have shown that the mechanistic features 
revealed by the rifampicin method are the same when T4 DNA 
is used as template (Hinkle, D. 1971. Ph.D. Thesis, 
University of California, Berkeley, cited by Chamberlin, 
1974). 
Based on these results, as well as the independent 
finding that EB does not inhibit the formation of non-
specific complexes between RNA polymerase and DNA (see 
Introduction), it was concluded that EB and DEMB inhibit 
either the recognition step or one of the initiation steps 
by a mechanism which may not involve an effect of these 
compounds on the rate constants of the two initiation steps 
(section 6c). However, in order to identify further the 
primary site of inhibition, the effect of DEMB on the 
recognition step, i.e., the formation of the first productive 
complex I, would have to be studied with respect to the rate 
constants and the number of enzyme molecules forming I com-
plexes in the presence and in the absence of inhibitor. 
Unfortunately, the formation of the I complex cannot, as 
yet, be stu~ied directly. Nevertheless, DEMB was shown not 
to affect the rate constants of the other steps of trans-
cription. Therefore, any method measuring the effect of 
the inhibitor on the maximum number and the maximum rate of 
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f total product formation may be used to study the effect of 
this inhibitor on the formation of the I complex. 
As already described in section 8 of the Results, 
the published methods for conducting experiments in the 
presence of a constant amount of inhibitor or in the 
presence of a fixed added ratio of inhibitor per DNA nucleo-
tide are not suitable for describing quantitatively the 
properties of the template for transcription. Instead, 
measurements should be carried out under conditions that 
produce a template of constant composition; i.e., at a 
constant bound inhibitor to DNA ratio. Only under such 
conditions the results would be informative as to whether 
a given template inactivator inhibits RNA synthesis by 
interfering with the rate terms of the reaction or the 
number of sites that are available on the DNA for the binding 
of the enzyme. 
The results of experiments conducted in the presence 
o·f a constant ratio of actinomycin D bound per DNA base 
(section 7a) revealed that this drug inhibits the rate of 
chain elongation by forming, with the propagating RNA poly-
merase, ternary ESI complexes which cannot yield further 
products causing termination of RNA chain growth. Howeverr 
Hyman and Davidson (1970) have suggested that the decreased 
rate of RNA chain growth is due to the fact that actino-
mycin D slows down the enzyme without forcing it to termin-
ate. A mechanism of inhibition for actinomycin D, in which 
1 1 1 
the transcribing enzyme can continue to synthesize product 
beyond an intercalated drug molecule at a reduced rate, 
would be kinetically equivalent to a model in which the 
ESI complex forms and breaks down to products at a rate 
different {slower) than that of the ES complex. Thus, 
if such a mechanism were correct, it would result, as 
show~ in Table 4, in smaller values for both Vint and 
Kint in disagreement with the experimental data obtained 
with actinomycin D {Figure 8). Of course, the possibility 
still remains that K1 = K3 or that either mechanism may 
operate depending on the conditions under which RNA poly-
merase is assayed. Indeed, according to a proposal by 
MUller and Crothers (1968), an elongating enzyme molecule 
may proceed past an intercalated actinomycin 0 molecule 
only if that molecule dissociates from the template in the 
time period required for the addition of the subsequent 
nucleotide to the growing chain; if not, the enzyme would 
be forced to terminate. If this model adequately described 
the mechanism of inhibition of chain elongation by actino-
mycin 0, then the enzyme in a ternary ESI complex would 
either terminate or slow down depending on the rate of 
chain elong~tion relative to that of actinomycin 0 dissocia-
tion from the template. Such rates depend on the temperature, 
the ionic strength and the type of the template. It is 
therefore possible that under the conditions of Hyman and 
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Davidson (0.4 ~ KCl, r 7 DNA) only a small fraction of RNA 
polymerase molecules would terminate when encountering an 
intercalated actinomycin D molecule while under the assay 
conditions of Figure 8 (0.2 ~ KCl, T2 DNA) a major fraction 
of the transcribing enzyme molecules does so. 
The results of the experiments conducted in the 
presence of a constant ratio of DEMB bound per DNA nucleo-
tide are discussed below. 
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1. A Model for the Inhibition of RNA Synthesis 
by Structural Analogs of Ethidium Bromide 
The derivation of equation 11• in section 7 of the 
Results which describes quantitatively the inhibition of 
RNA polymerase by EB, DEMB, DMEB and MAPEC was based on 
the following assumptions. 
1. Binary complexes between RNA polymerase and 
inhibitor (EI) do not form. 
2. RNA polymerase molecules participating in the 
formation of the first productive complex (ES) can trans-
cribe without being affected by the presence of inhibitor. 
3. Ternary complexes between the inhibitor (either 
free or template-bound) and a productive ES complex do 
not form. 
4. Inhibition is the result of the limitations 
imposed on the number of ES complexes that can form. The 
inhibitor binds to and distorts the conformation of speci-
fic DNA recognition sites to the extent that the enzyme 
cannot recognize such sites and form with them the first 
productive ES complex. 
5. The inhibitor prevents the formation of the first 
productive complex only, i.e., the formation of the recog-
nition complex I. Inhibition of the formation of a 
subsequent complex, e.g., the RS or the OP complexes, would 
be equivalent to diverting some of the already formed ES 
complexes into ESI complexes in violation of the previous 
assumption (3}. 
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According to this mechanism, the primary site of 
inhibition Ql DEMB, ~, MAPEC and DMEB ~the recognition 
site for RNA polymerase~ the DNA template, and the active 
form of the inhibitor~ the intercalated ~molecules at 
the recognition site. This conclusion is supported by the 
results of the experiments conducted with y- 32 P-labelled 
nucleotides and rifampicin which demonstrated that neither 
the rate of chain elongation nor the rate constants of the 
two initiation steps are affected by the presence of the 
inhibitors. The fact that, in the presence of a constant 
rb of DEMB, the maximum rate of the reaction remains 
identical to that of the uninhibited reaction (Table 4} 
indicates that inhibition is the result of a decrease in 
the number of chains that can be initiated, not the result 
of a decrease in the rate constants governing RNA chain 
initiation. Otherwise, if it were assumed for a moment 
that the reason for the observed inhibition is retarded 
initiation, then, at infinite template concentration 
carrying a given rb of inhibitor, a fraction of the enzyme 
would still be retarded and the value of Vmax would appear 
to be decreased. 
However, a word of caution concerning a possible 
misinterpretation of the experimental evidence may be 
needed here. , The results of the kinetic experiments in the 
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presence of a constant rb of DEMB were interpreted to 
indicate that inhibition by this compound is not the result 
of a decreased rate of recognition. Yet, DEMB may indeed 
alter the rate of recognition without contributing measura-
bly to the overall inhibition, since the half-life for 
recognition (~20 sec, Chamberlin, 1974} is much shorter 
relative to the time of pre-incubation of the enzyme-DNA 
complex (7.0 min) as well as the incubation time (7.0 min). 
Nevertheless, even if the rate of recognition is slower 
in the presence of DEMB, its magnitude is not altered 
enough for it to become an important contributor to the 
overall inhibition. 
Inhibition by EB, DEMB, DMEB and MAPEC is a measure 
of the ratio of inhibitor-distorted vs. inhibitor-free 
recognition sites which, naturally, depends on the value 
of rb of each inhibitor. Therefore, other factors being 
equal, the inhibitory capacity of compounds obeying this 
mechanism should only be dependent upon their affinities 
for the recognition site en the template. In other words, 
the inhibitory capacity of the template-bound forms of this 
class of inhibitors should not vary among the individual 
compounds. 
Yet, differences were observed among the inhibitory 
effectiveness of the intercalated forms of ethidium bromide 
and its structural analogs. Specifically, intercalated 
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molecules of EB inhibit RNA synthesis more effectively than 
intercalated molecules of DEMB, DMEB, or MAPEC (Table 3). 
A reasonable explanation for the observed differences 
in the inhibitory effectiveness of the intercalated phen-
anthridines, which is compatible with the experimental 
evidence, is presented below. 
a. The Inhibitory Effectiveness of the Drug-
DNA Complex may be a Function of its 
Dissociation Rate Constants 
Every intercalated inhibitor molecule must exist in 
a state of dynamic equilibrium with its free form in 
solution. At any concentration of DNA and inhibitor, the 
fraction of inhibitor molecules located within the inter-
calation site-is naturally determined by the magnitude of 
the association constant, while the average life-time that 
an inhibitor molecule spends in the intercalation site is 
determined by the magnitude of the dissociation rate 
constant of the template-bound inhibitor. In other words, 
the dissoci~tion rate constant, kdiss' of a given inhibitor 
will determine, to a large extent, the time period for 
which an inhibitor molecule intercalated at the recognition 
site will maintain this site distorted (see p. 111 ). 
If within this time period, the distorted recognition 
site happens to be approached by an enzyme molecule, 
recognition will not take place and a productive complex 
will not form. If, on the other hand, the inhibitor 
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happens to dissociate at a time when an enzyme molecule is 
in the vicinity of the recognition site and within a 
distance permitting formation of the I complex, the inhi-
bitor will be "substituted" by the enzyme on the recogni-
tion site. This is expected, because the latter has a much 
higher affinity for the template (5-6 orders of magnitude) 
than the inhibitor--mainly due to a kdiss of the inhibitor 
8-10 orders of magnitude smaller than the kd. of the lSS 
enzyme (Bresloff and Crothers, 1975; Chamberlin, 1974). 
Thus, intercalated inhibitor molecules which dissociate 
more slowly from the template would be stronger inhibitors 
of RNA synthesis since the enzyme is given less time for 
forming a productive complex at a site unoccupied by 
inhibitor. Therefore, the order of inhibitory effectiveness 
of the template-bound forms of compounds like EB, MAPEC, 
DEMB and DMEB which follow the mechanism of inhibition of 
RNA synthesis described quantitatively by equation 11', 
should be inversely related to the magnitude of their 
dissociation rate constants. 
For any of these inhibitors and at any rb below ri' 
two kinds of recognition sites exist in solution: a) 
inhibitor-free sites on which the enzyme can form produc-
tive complexes at its normal rate and b) inhibitor-carrying 
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sites which the enzyme cannot recognize except during the 
time the inhibitor momentarily dissociates from them. The 
inhibitor-free and the inhibitor-carrying sites are of 
course in dynamic equilibrium with one another (as well as 
with the rest of the DNA molecule) via the free form of 
the inhibitor and their relative population would be deter-
mined by the value of rb. 
When RNA polymerase is mixed with DNA at 0°C and then 
is incubated at 30°C for increasing periods of time before 
being assayed for RNA synthesis, a sharp increase in 
enzymatic activity at short pre-incubation times is observed 
followed by a much slower rise in activity at longer pre-
incubation times (see section 6b of Results). This biphasic 
dependence of enzymatic activity on pre-incubation time may 
be interpreted as follows: The early sharp rise in activity 
may be associated with the formation of the recognition I 
complex on inhibitor-free sites and the much slower rise 
in activity may be attributed to the slow ''displacement" 
of the inhibitor by the enzyme from the inhibitor-carrying 
recognition sites. The same interpretation could also be 
given to the biphasic character of the curves describing 
the formation of the cellulose-nitrate non-filterable 
complex reported by Richardson (1973a). 
According to this explanation, the displacement rate 
of the inhibitor from the DNA recognition site by RNA 
polymerase would be of the order of several minutes. 
However, the two reactions determining the rate of dis-
placement, i.e., the dissociation of the inhibitor from 
the DNA and the rate of recognition, are much faster 
{k - 2 -l B B 1 processes dissociation - 10 s for E ; res off and 
Crothers, 1975; t 112 recognition ~ 20 sec, Chamberlin, 
1974). Therefore, the rate of displacement should be a 
much faster process, having a half-life of the same order 
of magnitude as the recognition reaction. If, however, 
a recognition site is inactivated only when more than one 
inhibitor molecules are present, then, the period of time 
for which such a site would remain inhibitor-free, i.e., 
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available for recognition, would be much smaller. In this 
case, the rate of substitution could easily be of the order 
of several minutes. In fact, the results shown in Figure 
4 provide some indication that more than one inhibitor 
molecules are req~it·ed for inactivating a recognition site. 
At· l~ast in the case of DEMB and DMEB, inhibition is not 
observed until approximately one inhibitor molecule is 
bound per 17 base pairs, a value close to the estimated 
size ("-'20 base pairs; Heyden~~., 1975) of the recogni-
tion site, while total inhibition is observed at an rb of 
0.08 which corresponds to approximately three inhibitor 
molecules bound per recognition site. 
As mentioned previously, the order of inhibitory 
effectiveness of the template-bound forms of EB, DEMB, DMEB 
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MAPEC should be inversely related to their dissociation 
rate constants. These parameters, though, have not been 
measured for the structural analogs of EB. Nevertheless, 
the magnitudes of the dissociation rate constants have been 
measured for the intercalated form of proflavine, another 
inhibitor of RNA synthesis which forms with DNA similar 
complexes like those of ethidium bromide. It was found 
that the magnitude of the dissociation rate constant of 
intercalated proflavine decreases as the temperature .of 
the environment is decreased and as the ionic strength is 
increased {Li and Crothers, 1969). Accordingly, if the 
inhibitory effectiveness of the template-bound form of 
proflavine were indeed a function of the dissociation rate 
constant of its DNA complex, then, intercalated proflavine 
should be a stronger inhibitor at lower temperature and 
higher ionic strength. The inhibitory strength of template-
bound proflavine has not been determined as a function of 
these two parameters. However, the intercalated form of 
ethidium bromide is indeed found to be a more effective 
inhibitor at lower temperatures and higher ionic strengths 
(Richardson and Parker, 1973). Due to the similarities of 
the DNA complexes of the two drugs, it may be assumed that 
the dependence of the kdiss of the DNA-EB complex on ionic 
strength and temperature most probably parallels that of 
the proflavine-DNA complex. Therefore, the fact that the 
template-bound form of EB is found to be a more effective 
inhibitor at low temperatures and higher ionic strengths, 
i!e., under conditions favoring slower dissociation of the 
drug-DNA complex, is consistent with the idea that the 
inhibitory effectiveness of the intercalated phenanthrid-
ines is a function of the magnitude of the dissociation 
rate constant of their template-bound forms. 
121 
However, due to the indirect nature of the evidence 
discussed above, alternative explanations for the observed 
differences in the inhibitory effectiveness of the template-
bound phenanthridines must be considered. 
A serious obstacle in the quantitative treatment of 
the system under study has been the lack of information 
concerning the exact stoichiometry between the inhibitor 
and the template, i.e., how many inhibitor molecules 
inactivate how much of the template. Related to this 
problem, also, are the lack of information concerning the 
exact nature of the DNA structural features involved in 
enzyme recognition, as well as the possibility that the 
structural analogs of EB possess some degree of preference 
(binding specificity) for interaction only with certain 
types of DNA bases. Thus, if the inhibitors under 
comparison exhibited binding specificity, a direct com-
parison of the inhibitory effectiveness of their bound 
forms would not be possible on the basis of plots of 
f 
t 
' 
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activity~· rb of the type shown in Figure 4, since the 
relationship rb = rb would not necessarily hold true 
(rb is the ratio of inhibitor bound per recognition site 
as opposed to rb, the ratio of inhibitor bound per deoxy-
nucleotide). One, then, might postulate that the observed 
differences in the inhibitory effectiveness of the bound 
analogs of ethidium bromide are due to differences in their 
bfnding specificities for the template. 
This possibility, however, seems unlikely since at 
least ethidium bromide exhibits no preference for promoter 
sites on DNA molecules (Giacomoni ~ ~·, 1974). The bind-
ing constants and the maximum number of binding sites for 
ethidium bromide of DNA molecules having base compositions 
varying between 35% and 72% in G + C content have been 
found to be almost identical and the small differences 
observed do not correlate to the G + C content of the DNA 
(Waring, 1965b). These results have, since, been inter-
preted to indicate lack of binding specificity for ethidium 
bromide. No evidence for binding specificity on the part 
of the analogs of ethidium bromide is available, except 
for the linearity of the Scatchard plots (Figure 1; 
Kindelis, 1976) which may be interpreted to indicate lack 
of significant binding preference for these compounds. 
The situation, however, appears to be different in com-
plexes of ethidium bromide with dinucleotides, in which 
ethidium bromide exhibits some preference for interaction 
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with pyrimidine-purine sequence isomers (Krugh et al., 1975). 
--
Yet, the results of binding specificity or conformation 
studies of EB dinucleotide complexes may not be representa-
tive of the properties of the DNA ethidium bromide complex 
(Tsai et ~., 1975}. 
A second possible explanation for the observed 
differences in the inhibitory effectiveness among the bound 
forms of the structural analogs of ethidium bromide must be 
considered. One might be tempted to explain this phenomenon 
by a mechanism in which intercalation of one (or more) EB 
molecules distorts the conformation of a recognition site 
to a larger extent than DEMB so that, in the latter case, 
some degree of recognition with subsequent for-mation of 
productive complexes may take place. Alternatively, one 
might postulate that the presence of the bulkier phenyl 
group on the intercalated phenanthridinium ring of EB 
interferes with recognition more effectively than the smaller 
substituents on DEMB. Both of these mechanisms, however, 
should require partial recognition by the enzyme of a DNA 
site carrying one (or more) inhibitor molecules; i.e., a 
process equivalent to assuming formation of ternary ESI 
complexes. Such a mechanism would be in disagreement with 
the mechanism of inhibition by DEMB if the latter would 
occur through the inhibition of the formation of an ESI 
complex. Had the formation of a ternary complex been 
responsible for the observed inhibition, the kinetic 
pattern in the presence of a constant rb of DEMB would 
resemble that of actinomycin D, in contradiction with 
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the experimental findings. Therefore, although partial 
recognition by RNA polymerase of inhibitor-distorted 
sites on the DNA does probably take place, either its ex-
tent and/or its duration is presumably such that it does 
not constitute a major contribution to the overall inhibi-
tion by compounds of the same kinetic behavior as DEMB. 
b. The Magnitude of the Dissociation Rate 
Constants May Distinguish Inhibitors of 
Chain Initiation from Inhibitors of 
Chain Elongation 
A comparison of the dissociation rate constants of 
actinomycin D, proflavine and EB reveals that the dissocia-
tion rate constant of the ''pure" elongation inhibitor 
actinomycin D is at least 3-4 orders of magnitude slower 
than that of proflavine (Li and Crothers, 1969; MUller and 
Crothers, 1968}. The latter inhibits RNA chain initiation 
to the same extent as RNA chain elongation (Maitra et !l·• 
1967). In turn, the dissociation rate constant for 
proflavine is half an order of magnitude lower than the 
dissociation rate constant for EB which inhibits RNA chain 
elongation to a smaller degree than proflavine (Bresloff 
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and Crothers, 1975). It thus appears that intercalators 
having small dissociation rate constants inhibit perhaps 
mainly RNA chain elongation (covalently bound intercalators 
would be the extreme class of elongation inhibitors). On 
the other hand, compounds having high dissociation rate 
constants from the template inhibit mainly RNA chain 
initiation. This differentiating effect of the magnitude 
of the dissociation rate constants on the mechanism of 
inhibition of RNA synthesis by DNA intercalators could 
perhaps be the result of two factors: a) the different 
mechanisms of chain recognition and chain elongation by 
RNA polymerase and b) the small target size of the recog-
nition site {~V20 base pairs; Heyden et .!]_., 1975) relative 
to the size of the "elongation site" (up to 10,000 base 
pairs; Bremer, 1970). Because of these two factors a 
slowly dissociating intercalator at low values of rb would 
inhibit elongation. Under these conditions the majority 
of the recognition sites would remain inhibitor-free due 
to their small target size and, therefore, initiation would 
not be inhibited. In contrast, a fast dissociating inter-
calator at low values of rb would not affect elongation 
despite the. fact that the elongation site would be loaded 
with inhibitor molecules. Also, at first, initiation would 
not be inhibited because of the small target size of the 
recognition site. In the latter system at higher values of 
r 
' ' 
rb, however, the recognition sites would be loaded with 
inhibitor molecules and the overall inhibition of RNA 
synthesis would parallel the inhibition of initiation. 
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2. The Molecular Basis of the Trypanocidal 
Activity of the Phenanthridines 
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It has been postulated that the trypanocidal activity 
of various phenanthridinium compounds resides in the capacity 
of these compounds to intercalate into the DNA templates and, 
as a result, interfere with the biological functions and/or 
the metabolism of these macromolecules {Waring, 1970). 
In an attempt to determine the effect of the phenan-
thridines on particular functions of the DNA molecule·and 
possibly identify the primary target of their pharmacolog-
ical action, the inhibitory effectiveness of a number of 
phenanthridines against enzymes utilizing DNA as template 
or substrate was compared with the trypanocidal activity of 
these compounds (Kindelis, 1976}. The results obtained 
with DNA polymerase I and pancreatic deoxyribonuclease 
suggested that the pharmacological action of the structural 
analogs of ethidium bromide may not parallel their effective-
ness as inhibitors of these enzymes in vitro (Kindelis, 1976). 
Therefore, the property of the structural analogs of EB to 
inhibit strongly at least one enzyme catalyzing DNA repair 
and one enzyme catalyzing DNA degradation does not appear to 
be directly related to the pharmacological action of these 
compounds. 
In contrast, with the exception of DMNt, the order but 
not the magnitude of inhibition of RNA synthesis by a number 
of structural analogs of EB is found to parallel their 
trypanocidal activity (Table 2). Consequently, the 
pharmacological activity of the phenanthridines appears 
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to be directly related to the ability of these drugs to 
inhibit transcription by impairing the template properties 
of the DNA. According to the evidence discussed pre-
viously, one could propose that the capacity of at least 
some of the structural analogs of EB for template inactiva-
tion may be determined by the magnitude of the dissociation 
rate constants of their DNA complexes. According to this 
hypothesis, the variation in trypanocidal activity among 
these drugs could in turn be a function of the variation 
in the magnitude of the dissociation rate constants among 
the various phenanthridinium derivatives. 
In the recent past substantial efforts have been 
directed at elucidating a possible relationship between 
the affinity for DNA of compounds believed to act by 
associating with this macromolecule and the carcinostatic 
properties of these compounds (Le Pecq ~ !!·• 1974). 
Some studies have also entertained the possibility of a 
close relationship between the extent of conformational 
distortion of the double helix upon drug binding and drug 
action (Wakelin and Waring, 1974). However, in view of 
the present findings with the structural analogs of ethidium 
bromide and actinomycin 0, attention should be called to one 
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additional parameter, namely the dissociation rate constants 
of the drug-DNA complex, which might also play an important 
regulatory role in drug action. At least in the case of 
inhibition of transcription by intercalating compounds this 
parameter might turn out to be the factor that determines not 
only whether a given drug causes inhibition of RNA chain 
elongation or initiation but also, which one, among inhibi-
tors having identical mechanisms of action, will exert the 
strongest overall effect on RNA synthesis. 
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SUMMARY 
The mechanism of inhibition of DNA-dependent RNA 
polymerase of I· coli K-12 by structural analogs of ethid-
ium bromide has been investigated in an in vitro system 
utilizing T2 DNA as template. 
Ethidium bromide analogs carrying large hydrophobic 
groups at position ! of the phenanthridinium ring system 
are the strongest inhibitors of RNA synthesis. 
All of the compounds examined appear to inhibit RNA 
synthesis as a result of their affinity for DNA by inactiva-
ting template molecules rather than enzyme molecules. The 
concentration of DNA-template bound drug, which is the active 
form of the inhibitor, is found directly related to the 
degree of inhibition of RNA polymerase. Furthermore, 
identical amounts of various template-bound inhibitors effec.t 
inhibition to different extents. These differences may be 
attributed to the individual structural characteristics of 
these drugs. 
Measurements of the simultaneous incorporation of [ 3H]-
uridine triphosphate and y-[ 32 P]-adenosine and guanosine 
triphosphates revealed that phenanthridines inhibit mainly 
the initiation step of RNA synthesis with very little or no 
effect on the process of RNA chain elongation. It thus 
appears that ethidium bromide and its analogs inhibit 
differentially one or more of the steps recognized in RNA 
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chain initiation. Inhibition by these compounds might be 
the result of interference with the number of enzyme 
molecules attached to initiation sites or with the rate at 
which these molecules can initiate the synthesis of an 
RNA chain. Both mechanisms may also be involved. To test 
these alternatives, the rate and the number of enzyme 
molecules that proceed through individual initiation steps 
were measured in the presence and in the absence of inhibi-
tor. The inhibitor was found to have no effect on the rates 
of either one of the initiation steps. The number of enzyme 
molecules that are proceeding through these steps, in the 
presence of ethidium bromide or its analogs was, however, 
dramatically reduced. 
The reduction in the number of enzyme molecules which 
are able to proceed through the initiation events may be 
attributed either to an interference with the formation of 
the first recognition complex or to a decrease in the number 
of productive complexes that can form subsequent to recogni-
tion. These two alternatives were distinguished by deter-
mining the dependence of enzymatic activity on template 
concentration in the presence of a constant ratio of bound 
inhibitor to the DNA-template. The results are in good 
agreement with the theoretically predicted behaviour of 
inhibitors which act by preventing enzyme recognition of 
template binding sites. Such sites are apparently distorted 
as a result of intercalation of the drug. 
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The data also indicate that displacement of the 
inhibitor from the recognition site by direct interaction 
between RNA polymerase and the inhibitor-''recognition" site 
complex does not take place. Consequently, it appears that 
the enzyme may be able to recognize and bind productively 
and irreversibly only to recognition sites which are 
momentarily free of inhibitor. Therefore, the differential 
inhibitory effectiveness of the DNA complexes formed with 
structural analogs of ethidium bromide may be related ·to 
differences among the dissociation rate constants of these 
complexes. 
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APPENDIX 
I. Explanation of Symbols 
s 
(so) 
(s) 
I 
(i) 
(si) 
E 
(eo) 
(e) 
(es) 
(esi) 
K' 1 
KI 
DNA 
Total DNA concentration 
"Inhibitor-free" DNA concentration 
Inhibitor 
"Free" inhibitor concentration 
DNA-inhibitor complex concentration, 
i.e. bound inhibitor concentration 
Inhibitor bound per DNA nucleotide 
(molar ratio) 
Enzyme 
Total enzyme concentration 
"Free" enzyme concentration 
Enzyme-DNA complex concentration 
Enzyme-DNA-inhibitor complex concentration 
Enzyme-DNA dissociation constant 
Apparent DNA-inhibitor association constant 
II. The Relationship Between (s) and (s ) 
- -- 0 
For an inhibitor interacting with a DNA site according 
to the expression 
S + I , SI 
the following relationship may be derived: 
(s) = (s ) 
0 
(s) 
(so) 
- (si) 
~= 1-(so) rb 
(s) == (1-rb)(s0 ) (1) 
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III. Kinetics of Template Inactivation 
a. Kinetic Scheme: 
b. 
j 
E 
[ 
1. 
2. 
3. 
4. 
5. 
s .< I ~s~ ~ I p 
SI ~ ESI~ 7 
_:Assumptions: 
ES does form and does yield product 
SI does form 
EI does not form 
ESI does form and does yield product 
On the time scale of the experiments described 
in this Thesis all steps are rapidly reversible 
with the exception of the formation of p from 
ES (or ESI). 
6. Reinitiation does not alter significantly the 
rate of the reaction. 
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c. Equations 
The following equilibrium expressions may be 
written to describe the reactions taking place under 
the scheme shown in Section Ilia of the Appendix. 
E = E + ES + ESI 
0 
(e0 ) = (e) + (es) + (esi) 
(e) = (e
0
) - (es) - (esi) 
E + S = ES 
(2) 
(es) = K1 (e)(s) = K1 {(e0 )-(es)-(esi)}(s) (3) 
S + I = SI 
(si) = K1 (s)(i) (4) 
E + SI = ESI 
(esi) = K3 (e)(si) = K3{(e0 )-(es)-(esi)}(s) (5) 
ES + I = ESI 
(esi) = K4 (es)(i) (6) 
(7) 
(8) 
d. Derivations 
Based on the general kinetic scheme shown in 
Section lila of the Appendix, the expressions for the 
ES and the ESI complexes are obtained as shown below. 
These expressions are subsequently used in deriving 
the equations describing each particular mechanism 
of inhibition. 
In order to obtain an expression for (es), 
equation (6) is substituted into equation (3): 
(es) = K1 (s)(e0 ) - K1 (s)(es) - K1K4(s)(es)(i) 
(es){1 + K1 (s) + K1K4(s)(i)} = K1 (e0 )(s) 
(es) = 
K1 (e 0 )(s) 
Using equation (8), the above expression can be 
transformed to: 
(es) = 
In order to obtain an expression for (esi), 
the expression for (es) from equation (6) is sub-
stituted into equation (5): 
(esi) 
(esi) {1 + = 
(esi) = 
1 + 
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(9) 
Using equation (8), the above expression can be 
transformed to: 
(esi) = 
1. Binding Site Inactivation 
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(10) 
pescription: It is assumed that ternary 
ESI complexes do not form. Therefore, 
K3 =o. Only binary ES complexes yield 
product. Therefore, V = k(e 0 ) and max 
the rate expression becomes 
v = k(es) 
Using equation (9), the general expression 
for (es), the above expression can be trans-
formed to: 
k(e
0
)•K1 (s) 
v = 
1 + K1 (s) + K3 (si) 
but it i.s assumed here that K3 :::o. Therefore, 
v = 
vmax(s) 
+ ( s) K' + (s) 1 
Substituting the expression for (s) from 
equation (1): 
v = 
V (1-rb)(s ) max o 
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1 1 K' 1 1 
+ 
1 (11) = --. . --
v Vmax v max (1-rb) (so) 
vmax K' 1 1 + 1 . -- (12) = 
v (1-rb) (so) 
2. "Rate" Inhibition 
Description: It is assumed that ternary 
ESI complexes form but do not yield 
product. The affinity of E for S is as 
strong as the affinity of E for SI; 
therefore, K1 =K3 . Only the ES complex 
can form product. Therefore, V = k(e ), 
max o 
and the rate expression becomes 
v = k(es) 
Using equation (9), the general expression 
for (es), the above expression can be trans-
formed to: 
v = = 
1 + K1 (s) + K3 (si) K3 + (s) + -(si) 
Substituting the expression for (s) from 
equation (1): 
v = 
K1 
v = 
V (1-rb) max 
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but, it is assumed here that K3 =K1 . Therefore, 
V (1-rb) max V ( 1-rb)(s ) max o 
v = 
1 + 
1 . 1 
= 
v 
Vmax 
= 
1 
v 
= 
+ 
+ 
K' 1 
1 
. --
(s ) 
0 
1 
.__,_ (13) 
(14) 
3. Mixed Binding §ite Inactivation 
D<~script ion: 
ESI complexes 
the same rate 
affinity of E 
affinity of E 
It is assumed that ternary 
form and yield product at 
as the ES complexes, but the 
for S is different than the 
for SI. Therefore, K1 f K3 , 
V = k(e ) and the rate expression max o · 
becomes 
v = k(es + esi) 
Using equations (9) and (10), the general 
expressions for (es) and (esi), the rate 
expression becomes 
v = 
v = 
k{K1 (e0 )(s) + K3 (e0 )(si)} 
1 + K1 (s) + K3(si) 
V {K1(s) + K3(si)} max 
Substituting the expression for (s) from 
equation (1): 
v = 
Vmax{K1 (1-rb)(s 0 ) + K3(si)} 
1 + K1(1-rb)(s0 ) + K3(si) 
and dividing by (s ): 
0 
v = 
v = 
1 
v 
V rna::·: 
v 
Vmax{K1( 1-rb) +K3•rb} 
--
1
-- + K1 (1-r ) + K3 ·rb (s ) b 
0 
Vmax{K1 - rb(K1-K3)}(so) 
1 + {K1-rb(K1-K3 )}(s0 } 
1 1 1 
= 
---- + -----------------·----
vmax V {K1+rb(K3-K1 )} (s ) max . o 
1 1 
= 1 + 
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(15) 
(16) 
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4. Mixed Inhibition 
Description: It is assumed that ternary 
ESI complexes form and yield product at 
a different rate than binary ES complexes, 
but the affinity of E for S is different 
than the affinity of E for SI. Therefore, 
K1 r K3 and the rate expression becomes 
v = k(es) + k(esi) 
Using equations (9) and (10), the general 
expressions for (es) and (esi), the above 
equation becomes: 
v = 
k•K1 (e0 )(s) + k·K3 (e0 )(si) 
1 + K1 (s) + K3 (si) 
Substituting the expression for (s) from 
equation (1): 
v = 
(e0 ){k·K1 (1-rb)(s 0 ) + k•K3 (si)} 
1 + K1 (1-rb)(s0 ) + K3 (si) 
Dividing by (s )· 0 • 
v = 
v = 
{Vmax·K1( 1 -rb) + V~ax·K3•rb}(so) 
1 + {K1 (1-rb) + K3 •rb}(s0 ) 
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1 K1 (1-rb) + K3•rb 
= 
v V •K (1-r ) max 1 b + V' •K •r max 3 b 
+ 
1 1 (17) ·--
V •K ( 1-r ) 
max 1 b + V' •K •r max 3 b (so) 
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IV. Data for some figures 
a. Data for Figure 1. 
DNA 
A460 
If 
A460 
If 
(m~!) rb (Mxl0 4 ) (mH) rb (_!ix10 4) 
EB DEMB 
satd 0.420 satd 0.390 
0.945 0.478 0.0164 0.0171 
0.578 0.513 0.025 0.0274 0.578 0.528 0.0225 0.0501 
0.399 0.550 0.033 0.0383 0.399 0.573 0.0285 0.0664 
0.263 0.610 0.044 0.0560 0.263 0.631 0.035:~ 0.0875 
0.137 0.725 0.060 0.0899 0.137 0.721 0.0439 0.1201 
0.074 0.823 0.072 0.1188 0.074 0.784 0.0504 0.1430 
1. 003 0.1719 0.886 0.1800 
isosbestic points at: 390, 383, 496 nm 
512 nm 
MAPEC DMEB 
satd 0.612 satd 0.485 
0.840 0.702 0.0198 0.0373 0.840 0.560 0.0209 0.0357 
0.525 0.749 0.0280 0.0567 0.525 0.601 0.0297 0.0552 
0.347 0.802 0.0361 0.0787 0.347 0.647 0.0386 0.0772 
0.221 0.866 0.0447 0.1052 0.221 0.703 0.0486 0.1038 
0.137 0.931 0.0525 0.1321 0.137 0.764 0.0572 0.1329 
0.074 1. 000 0.0586 0.1607 0.074 0.825 0.0667 0.1619 
1.104 0.2038 0.928 0 . 2110 
isosbestic points at: 370, 380, 49 2 nm 
460 nm 
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b. Data for Figure 2. 
DNA DNA 
mM cpm mM cpm 
no inhibitor + DEMB 
0.010 11130 0.016 2615 
0.016 15817 0.026 4490 
0.026 19648 0.036 6121 
0.044 26079 0. 0 so .6912 
0.072 9710 
+ MAPEC + DMEB 
0.016 10,416 0.016 736 
0.016 9,935 0.026 1420 
0.026 19,480 0.036 2185 
0.026 18,529 0.050 2667 
0.036 30 '39 7 0.072 5131 
0.036 31,448 
0.056 51,634 
0.056 43, '767 
Plotted values for DEMB and DMEB have been multiplied 
by 12.5 and for the uninhibited reaction by 2.78 in order 
to normalize the various specific activities of XTP used 
in each reaction. 
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c. Data for Figure 3a. 
I I 
(lJ~!) activity, (%) (lJ~) activity, (%) a 
EB DEMB 
2.39 82.5 4.6 6.65 91.7 6.7 
4.78 59.2 3.8 11.64 74.4 6.6 
7.16 40.5 3.8 14.97 60.3 6.4 
7.96 25.8 0.2 18.29 42.5 4.8 
9.55 21.9 3.6 23.28 22.3 . 2. 4 
11.14 10.9 1.8 28.27 11.6 0.0 
15.12 4.5 0.4 44.90 2.0 0.0 
27.06 0.0 56.54 0.0 
MAPEC DMEB 
5.24 98.6 1.6 5.95 94.2 7.8 
6.98 82.2 4.2 10.41 79.9 6.5 
8.73 74.8 2.1 13.38 60.0 6.0 
10.48 53.6 2.6 17.84 33.5 3.8 
12.22 38.2 5.8 20. 81 20.5 2.6 
13.97 29. 7 3.5 26.77 9.9 0.4 
15.71 19.6 1.5 50.56 0.0 
19.21 11.5 1.1 
59.56 0.0 
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d. Data for Figure 3b. 
I activity, I activity, I activity, 
(l-1~!) (%) (l-IM) (%) ( l-1~!) (%) 
DMNC MAPAC DDEB 
1.1 97.8 2 0 2 95.0 2 0 2 95.0 
1.8 92.0 4.4 86.0 5.0 92~0 
2.3 83.0 6.8 79.5 9.0 80.0 
2.3 75.0 9.0 70.0 9.0 83.0 
3.0 81.5 9.0 78.0 12.4 65.0 
3 0 5 89.0 11.4 62.0 12.4 60 0 5 
4.0 74.5 12.5 52.0 17.0 44.5 
5.3 68.5 13.6 46.5 21.0 27.5 
7.1 12.5 17.0 37.0 29.0 14.5 
8.8 9.0 21.0 24.5 48.0 4.0 
8.8 12.0 28.7 12.0 52.4 2.0 
9. 5 51.0 48.2 2.0 
10.7 18.5 
13.0 8.0 
15.0 6.0 
18.0 1.5 
30.0 0.0 
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e. Data for Figure 5. 
I activity, (%) activity, (%) 
(~M) A starters a G starters a 
EB 
2.39 103.0 11.8 89.1 10.9 
4.78 79.7 7.1 60.9 8.0 
7.16 60.1 12.6 49.4 13.8 
7.96 47.1 5. 7 
9.55 17.2 9.1 
11.14 28.7 8.9 
15.12 5.3 0.7 
27.06 0.0 0.0 
DEMB 
6.65 97.5 1."2 66.3 10.5 
11.64 103.1 5. 5 51.8 11.3 
14.97 72.0 11.3 40.3 11.2 
18.29 40.6 13.9 31.7 9.8 
23.28 30. 5 4.0 13.7 4.0 
28.27 4.9 2.0 
56.54 0.0 0.0 
MAPEC 
5.24 110.0 9.5 
6.98 58.7 15.2 
8.73 76.8 3.0 
10.48 36.4 9.9 
12.22 52.0 3.5 
LL97 9.5 3.0 
15.71 33.0 2.1 
19.21 1.4 1.0 
59.56 0.0 0.0 
Continued on following page. 
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e. Data for Figure 5 (continued) 
I activity, (%) activity, (%) 
(llM) A starters a G starters a 
DMEB 
5.95 103.9 11.9 67.9 5.9 
10.41 85.6 14.0 63.3 11.8 
13.38 65.0 7.4 45.2 15.6 
17.84 39. 2 8. 5 22.3 9.9 
20.81 28.7 2.3 10.8 4.9 
26.77 1.5 
50.56 0.0 0.0 
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Data for Figure 5 (continued) 
I [3H], (%) 
( M) [32P], (%) 
EB MAPEC DEMB DMEB 
2.4 0.95 
4.5 0.80 
7.0 0.78 
7. 5 0.96 
9.5 0.70 
10.0 0.90 
10.5 1. 00 
11.5 0.85 
12.5 0.85 
13.5 0.97 
15.0 0.80 0.90 
18.0 0.90 0.95 
21.0 0.85 
23.5 0.85 
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f. Data for Figure 8. 
DNA I 
-ll~ llM cpm cpm (J 
10 10410 
10 10764 11130 956 
10 12215 
16 14030 
16 17218 15817 1629 
16 16203 
26 19690 
26 19587 19648 54 
26 19667 
44 26438 
44 25918 26079 312 
44 25880 
Act. D 
8 0.0153 3357 
8 0.0153 3125 3252 117 
8 0.0153 3273 
12 0.0193 5541 
12 0.0193 5831 5479 386 
12 0.0193 5066 
20 0.0273 6805 
20 0.0273 7450 7694 1032 
20 0.0273 8826 
34 0.0413 10009 
34. 0.0413 10056 10132 175 
34 0.0413 10333 
DEMB 
8 16.82 3270 
8 16.82 3287 25 
8 16.82 3305 
12 17.04 5557 
12 17.04 5453 5059 774 
12 17.04 4167 
20 17.48 7293 
20 17.48 5895 7461 1656 
20 17.48 9195 
34 18.25 11665 
34 18.25 11756 11605 189 
34 18.25 11393\ 
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